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ABSTRACT

STUDY OF THE HIV-1 GENE REGULATORY PROTEINS TAT AND REV
BY THE TWO-HYBRID SYSTEM IN YEAST

David Allen Elkins

Tat and Rev, small proteins encoded by the Human Immunodeficiency
Virus type 1 (HIV-1), regulate its pattern of gene expression within infected
cells. Tat increases transcription from the integrated provirus by
approximately a thousand-fold; Rev effects a shift in the pattern of splicing of
the viral mRNA. Both are likely to interact with cellular proteins in
executing their respective functions. Tat has additional activities (including
neurotoxicity and inhibition of lymphocyte activation) which may be
extraneous to its viral functions.
In order to identify cellular proteins interacting with Tat and Rev, the
genes for both were cloned into plasmid vectors of the yeast two-hybrid
system. This system enables large-scale screening of the members of a cDNA
library for interaction with a protein of interest by the functional
reconstitution of the GAL4 transcriptional activator.
The search for Rev-interacting proteins from a mouse embryo cDNA
library was conducted with a one-reporter-gene strain of yeast; all of the initial
candidate Rev-interacting proteins were later demonstrated to be falsepositives. A two-reporter-gene yeast strain was used to identify Tat-

interacting proteins from the same library, enabling rapid elimination of
false-positives from consideration. A total of twenty-two Tat-interacting
proteins were found, one of which was a partial cDNA for a novel brain
extracellular matrix protein. A "spurious PCR" strategy was used to clone
additional 5' fragments of the cDNA until all 2457 nucleotides of coding
sequence (and a small 5' untranslated sequence) were obtained. This protein
contains nine epidermal growth factor-like (EGF-like) repeats, cysteine-rich
motifs of about forty amino acids which may mediate intra- and inter-protein
binding.
The significance of Tat's interaction with this brain protein remains
uncertain. The interaction may be "bridged" or mediated by an endogenous
yeast protein, probably a transcription factor, since the original fragment of
the protein strongly activates transcription when tethered to a promoter. Its
function in the developing and mature nervous system remains to be
discovered.
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CHAPTER ONE
INTRODUCTION

A. AIDS and HIV
Infection with the Human Immunodeficiency Virus (HIV), and its
attendant disease AIDS (Acquired Immune Deficiency Syndrome), has
erupted into the human population in the span of just two decades. Over
400,000 AIDS patients have been identified in the United States and almost a
million AIDS patients worldwide (ADS Supplement, Dec. 1994 and Jan.
1995). Perhaps twenty times as many people are infected with the Human
Immunodeficiency Virus (HIV) and will progress to AIDS within ten years
(Palca, 1991). Barring development of an effective treatment, AIDS will kill
all its victims. Baltimore (1995) succinctly captures the challenge of HIV
infection: "The key fact about HIV is that it is a nonequilibrium infectious
agent," implying that spread of the virus is not a steady-state phenomenon.
Indeed, the incidence of HIV infection adds thousands of victims every year,
with the rate of infection alarmingly high among teenagers (Lindegren et al.,
1994).
HIV is not a casually-transmissible agent. Spread occurs primarily
through sexual intercourse or through shared needles in intravenous drug
abuse (Brookmeyer, 1991). However, prior to widespread testing of donated
blood in the United States in 1985, an estimated 10,000 hemophiliacs
requiring regular transfusions were infected with HIV through contaminated
blood or blood products (Galel et al., 1995). Sadly, thousands of infants are
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born each year in the United States who have been infected in utero with HIV
and whose clinical course generally proceeds more rapidly to AIDS (Oxtoby,
1991; Douglas and King, 1992). It is disturbing that an infectious agent
transmitted almost exclusively by blood or semen continues to spread, despite
large-scale educational efforts.
Compared to other infectious diseases, AIDS is a relatively new disease.
The distinct clinical picture of AIDS was first noted when Kaposi's Sarcoma
(KS) began to appear, with unusual incidence and aggressiveness, in young
white homosexual males (Friedman-Kien et al., 1981). Previously, this rare
tumor of blood vessels (in the skin, oral cavity, or internal organs) had been
observed primarily as an indolent tumor occurring in older men of
Mediterranean descent (Gottlieb and Ackerman, 1982). Emergence of this
new form of KS was followed by an increase in Pneumocystis pneumonia in
the same population (Friedman-Kien et al., 1981). This combination of
symptoms pointed to an immune deficiency of infectious origin, and the
search for the infectious agent began.
This search culminated in 1983 with the isolation of HIV by both a
French and an American group (Barre-Sinoussi et al., 1983; Gallo et al., 1983).
Discovery of HIV-1 and the closely related HIV-2, has broadened the clinical
significance of an unusual family of viruses, the Retroviridae. Adult T-cell
leukemia/lymphoma, associated with Human T-Lymphotropic Virus
(HTLV-I) is the only other human disease strongly associated with a member
of this virus family (Sugamura and Hinuma, 1993). Another member of this
family, HTLV-II, may be involved in tropical spastic paresis and in certain
atypical hairy cell leukemias and other T-cell malignancies (reviewed by
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Thompson and Dalgleish, 1988). Neither agent rivals the medical importance
of HIV.
B. HIV - structural components
Retroviruses derive their name from the action of the virionassociated reverse transcriptase (Varmus, 1988). This enzyme inverts the
usual flow of genetic information (DNA to RNA). Once the virus has
entered the host cell and shed its coat, viral genomic RNA is converted into
proviral double-stranded DNA and then randomly integrated into a host cell
chromosome (Katz and Skalka, 1988). The first well-characterized
retroviruses were Rous sarcoma virus (RSV) and avian leukosis virus (ALV)
(Varmus, 1988). These viruses contain only three genes - Gag, Pol, and Env which encode the viral structural proteins and enzymes. These three genes
are common to all retroviruses.
Gag, Pol, and Env polyprotein precursors are processed into smaller,
active proteins (Katz and Skalka, 1991). The HIV-1 Gag precursor (Pr55) is
cleaved into several smaller proteins. Some of these form the outer shell of
viral particles, while another packages the retroviral genomic RNA into
virions. ("Gag" is a contraction of Group-antigen, a reference to early
serological classification of retroviruses). The Pol gene product (for
"Polymerase") is cleaved into proteins which carry out enzymatic activities
during the viral life cycle: protease, reverse transcriptase, and integrase (Katz
and Skalka, 1991). The low frequency (about 5%) of the translational
frameshift from the Gag to the Pol ORF (Open Reading Frame) ensures that
the structural proteins are produced at about a twenty-fold excess over the
enzymes (Oroszlan and Luftig, 1990). The Env ("Envelope") precursor (gp!60)
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is glycosylated and folded in the rough endoplasmic reticulum and Golgi
apparatus of infected cells. It is then cleaved into the mature envelope
proteins gp!20 and gp41, which are inserted into the cellular plasma
membrane (McCune et al., 1988). The virion acquires a lipid envelope
containing these proteins as it buds from the infected cell (Ozel et al., 1990).
The interaction of gpl20 with the cell surface protein CD4 mediates HIV
infection of a subset of human cells - primarily T-helper lymphocytes
(Dalgleish et al., 1984).
As noted, the three gene products discussed above are common to all
retroviruses. The more recently discovered retroviruses HTLV-I, HTLV-II,
HIV-1 and HIV-2, encode additional gene products and exhibit a more
complicated system of gene regulation (reviewed by Sagamura and Hinuma,
1993). Discovery of these additional regulatory proteins has led to the
classification of retroviruses as simple and complex (Cullen, 1992). Simple
retroviruses (such as RSV and ALV) encode only the three gene products
common to all retroviruses; expression of their genes is regulated entirely by
cellular factors. Complex retroviruses encode additional gene products which
alter expression of the viral genes and which are essential to viral replication
(Cullen, 1991; Rosenblatt, 1993).
Like other complex retroviruses, HIV (Figure 1) encodes regulatory
proteins that are essential for replication and maturation of viral particles
(Arya et al., 1985; Fisher et al., 1986; Siegel et al., 1986). Two of these proteins.
Tat and Rev, give HIV-1 a biphasic pattern of gene expression by modulating
cellular transcription and splicing of viral RNA. ("Tat" stands for Trans
activator of transcription; "Rev" denotes Regulator of virion expression.)
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These small RNA-binding proteins mediate transcriptional and posttranscriptional transactivation, respectively (for review, see Cullen and
Malim, 1991; Rosen, 1991; Vaishnav and Wong-Staal, 1991). Tat and Rev are
necessary for replication of HIV both in cell culture and in whole organisms.
Vpu

TAR element
Pol
Gag

.C^T/Rdrt/jrnscfcfpty.
5'LTR

Rev Response Element

/

Ypr
Yif

Nef

_L
s

Env
Tat

3’LTR

Rev

Figure 1. The genome of HIV-1. Genes are indicated by boxes and names;
RNA regulatory elements (TAR and RRE) are indicated by single arrows.
Average length of viral genome is about 9.0 kB.
Mutation of either gene, or mutation of their binding sites within the viral
mRNA (TAR and RRE, respectively), results in a non-replicating virus
(Sadaie et al., 1988). Both Tat and Rev are believed to interact with cellular
components as part of their regulatory functions (Rosen, 1991). The third
regulatory protein, Nef, is not essential to growth of HIV in cell culture but
has proven essential for replication in whole organisms (Kestler et al., 1991).
HIV also encodes "accessory" proteins which are not essential for replication
but exert more subtle effects on the course of viral infection (Vif, Vpr, Vpu)
(Geraghty and Panganiban, 1993; Heinzinger et al., 1994; Balliet et al., 1994).
Once integrated within the host cell DNA, the HIV genome becomes,
in effect, a cellular gene cluster. It is dependent on cellular RNA polymerase
II and associated factors for transcription (Jones and Peterlin, 1994); likewise,
the viral mRNA must be processed and spliced by cellular machinery (Rosen,
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1991). Tat and Rev modulate these cellular processes by interacting with
cellular proteins. Because the regulatory actions of Tat and Rev are essential
to viral replication, a better understanding of their mechanisms of action may
foster the development of more effective anti-HIV therapy.
In this overview, I will first outline HIV gene expression in general
and then detail the functions of Tat and Rev in regulation of HIV gene
expression. I will then examine the separate elements involved in Tatmediated transcriptional activation, including cellular factors binding to TAR
RNA and factors binding directly to the Tat protein.
My project has centered on the discovery of new mammalian proteins
binding to Tat. Characterization of such factors may elucidate the
mechanisms by which Tat activates HIV gene expression. While interactions
of Tat with cellular transcription factors have been described since the
initiation of this project (Jeang et al., 1993; Kashanchi et al., 1994), it is
uncertain whether these interactions represent the sine qua non of Tat
transcriptional activation.

Also, Tat has other actions besides transactivation

of the HTV LTR: Tat alters expression of several cellular genes by acting at
heterologous promoters (Rosenblatt et al., 1995); it also appears to have
extracellular effects unrelated to promoter-mediated gene regulation. These
aspects of Tat function are pertinent to my results and will be reviewed.
C. HIV-1 - gene expression and regulation
Expression of HIV-1 mRNA is biphasic: early in infection,
transcription occurs at a low level, and all transcripts undergo complete
splicing to 2kB mRNAs which encode the regulatory proteins Tat, Rev, and
Nef (Sodroski et al. , 1986). The unspliced (9kB) and singly-spliced (4kB)
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mRNAs do not reach the cytoplasm; therefore, the Gag, Pol, and Env gene
products are not present at this early stage. Later in infection, the Tat protein,
in collaboration with cellular factors, mediates high-level transcription of
proviral mRNA - at least a hundred-fold above the basal rate (Feinberg et al.,
1991). This results in greatly-increased levels of Tat, Rev, and Nef mRNAs
and proteins.
1. Rev and post-transcriptional regulation
At the same time, rising levels of Rev protein downregulate
cytoplasmic levels of fully-spliced HIV RNA and increase cytoplasmic levels
of unspliced and singly-spliced RNA (Malim et al., 1989a). These latter
mRNAs encode the viral enzymes and structural proteins;

unspliced RNA

also functions as the viral genome (Pomerantz et al., 1990; Pomerantz et al.,
1992). It is unclear whether this Rev-mediated shift in HIV gene expression is
due to direct inhibition of splicing or increased transport of HIV RNA from
the nucleus, or both (Steffy and Wong-Staal, 1991). In addition, Rev may
specifically enhance cytoplasmic translation of RRE-containing RNAs
(Lawrence et al., 1991; Pfeifer et al., 1991).
2. Tat and transcriptional regulation
The nuclear function of Tat has been extensively studied. It was
learned early that Tat increased levels of HIV RNA (Sodroski et al., 1985)
through increasing transcription of the viral mRNA (Muesing et al., 1987). A
point mutation abolishing only the Tat ORF led to a severe deficit in all
classes of viral transcripts (Sadaie et al., 1988) in HIV-infected cells,
demonstrating that Tat's transcriptional activation is essential to HIV
replication. However, transcription is a multi-step process; whether Tat
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increases initiation of transcription or promotes transcriptional elongation
(or both) remains controversial (Laspia et al., 1989).
3. Other roles of Tat
Tat may also play non-transcriptional roles in HIV gene regulation.
Early work suggested that Tat might both increase steady-state levels of HIV
RNA and enhance their translation (Cullen, 1986; Hauber et al., 1987). A
translational role for Tat in mammalian cells, however, has not been
supported (e.g., Laspia et al., 1989;) and it is unlikely that Tat plays any role in
the stability or transport of HIV RNA (Gentz et al., 1989). Tat can affect
translation of TAR-containing RNAs in some systems (notably Xenopus
oocytes) (Braddock et al., 1989; Braddock et al., 1990), but the relevance of this
effect to HIV biology remains unclear.
D. HIV transcription
1. Role of cellular factors
While Tat is a powerful transactivator critical for HIV transciption, it
does not act alone. Transcription of the integrated HIV provirus is dependent
on cellular transcription factors which recognize binding sites in the 5' LTR
(Jones and Peterlin, 1994). The 3' LTR determines termination and
polyadenylation of viral transcripts (Guntaka, 1993). The 5' LTR constitutes
an inducible and compact pol II promoter, containing numerous protein
binding sites and a TATA box near the transcription initiation site (Gaynor,
1992). It also contains elements more distal to the transcription initiation site
which act as enhancers.
Eukaryotic transcription requires coordinated action of many different
proteins (for review, see Zawel and Reinberg, 1995; McKnight, 1996). The
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three classes of RNA polymerase (RNA pol) - I, II, and III - do not bind
directly to promoter sequences but are recruited to the site of transcription by
proteins which bind to promoter DNA (Ptashne, 1988). For example, the
TATA box present in the majority of pol II promoters is recognized by the
TATA-box binding protein (TBP) acting in concert with at least eight cellular
proteins called TBP-associated factors, or TAFs (Goodrich and Tjian, 1994).
These factors coordinate assembly of a pol II transcription complex at the
promoter; specific properties of the complex - notably, its processivity, or
ability to elongate efficiently - are dependent in part on the particular
combination of proteins within the large complex (Goodrich et al., 1994).
Transcription is regulated largely by the medley of protein-binding
elements within a given promoter. Most promoters contain basal promoter
sequences which determine the class of polymerase and which direct a low
level of transcription (Buratowski, 1994). Separate modulatory elements
enhance or reduce this "basal" rate of transcription. Activators of
transcription can function through several mechanisms, including
recruitment of general transcription factors, conformational alterations of the
assembled transcription complex, and covalent modification of components
in the assembled complex (Tjian and Maniatis, 1994; Goodrich et al., 1994).
Both basal and modulatory elements function via proteins which bind to
them.
Transcription is a multistep process, consisting at a minimum of
initiation, promoter clearance, elongation, and termination (Tjian and
Maniatis, 1994). Different proteins act at different steps within this process.
Initiation seems to be the critical step for most promoters, and many different
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proteins act in concert to assemble the pre-initiation transcription complex
(Zawel and Reinberg, 1995). For example, the TATA element, found in the
majority of known promoters, binds the TATA-box binding protein (TBP)
directly as a prerequisite for transcription (basal and activated) in all
promoters containing a TATA box (Hernandez, 1993). However, TBP
enhancement of transcriptional activity requires the presence of other
proteins, termed "coactivators," in order to effect high levels of transcription
(Buratowski, 1994). TBP, a 38kD protein, is found in a cellular complex called
TFIID, which is approximately 750 kD in mammals (Klug, 1993). The size of
this complex (which itself is one of more than a dozen general transcription
factors) illustrates the theme of multiple proteins acting to initiate and
regulate the process of transcription (Tjian and Maniatis, 1994). Tat functions,
then, within a multiprotein context consisting of numerous potential
interaction partners.
Cellular proteins which bind to cognate DNA elements within the HIV
LTR and are known to modulate HIV transcription include Spl, NF-kappa B,
TBP, LEF, LBP-1, Oct, Ets-1, and USF (Gaynor, 1992; Jones and Peterlin, 1994).
Proteins whose binding sites are present within the LTR but whose
contribution to HIV transcription is unknown include NFAT, AP-1, COUP
and c-myb (Jones and Peterlin, 1994). Evidence now supports a direct
interaction between Tat and both Spl (Jeang et al., 1993) and TBP (Kashanchi
et al, 1994).
A basal level of transcription from the HIV LTR occurs in the absence
of Tat. The NF-kappa B sites contribute strongly to basal transcription
(Kamine et al., 1991; Michael et al., 1994), an effect mediated in part through
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reconfiguration of the chromatin surrounding the LTR (Pazin et al., 1996). In
contrast, the TATA box and Spl sites exert a marked effect on Tat-activated
transcription (Jones et al., 1986; Berkhout and Jeang, 1992). Basal transcription
is not dependent on the specific sequence of the LTR TATA box; however,
Tat-activated transcription is significantly perturbed by small changes in this
element (Berkhout and Jeang, 1992; Olsen and Rosen, 1992). Also, the specific
sequence of the HIV TATA box increased the effectiveness of Tat
transactivation over that seen with a heterologous TATA sequence (Huang
and Jeang, 1993). The proximity of the TATA box and Spl sites is crucial to
Tat-activated transcription but not to basal transcription (Huang and Jeang,
1993). Furthermore, the relative positioning of three promoter elements TATA box, Spl and Tat-binding site (TAR) - is crucial for Tat-activated but
not basal transcription from the LTR.
Functional studies have demonstrated a Tat-TBP interaction in vivo
(Veschambre et al., 1995), and this interaction is important for HIV
transcription. However, it remains uncertain whether Spl and NF-kappa B
are uniquely required for Tat-mediated transactivation of the HIV-1 LTR or
are replaceable. The presence of Spl sites was critical to Tat activation of a
heterologous promoter but not for activation of the same promoter by an
acidic activator (Kamine et al., 1993). In other studies, both the NF-kappa B
and Spl sites were replaced by several other promoter sequences without
inhibition of LTR-directed transcription (Madore and Cullen, 1995). A recent
study in primary human CD4 lymphocytes revealed that, in this setting, the
NF-kappa B sites within the HIV LTR are absolutely required for Tat
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transactivation (Alcami' et aL, 1995), suggesting that these elements are
required for HIV transcription in primary infection.
It is useful to view Tat as an "adaptor" or "coactivator" in the assembly
of the inducible transcription complex. An adaptor must be correctly
positioned in order to bind simultaneously to two (or more) transcription
factors within the complex (Martin, 1991). At the HIV promoter, the timing
of action and spatial positioning of several proteins - in particular. Tat, Spl,
NF-kappa B and the TATA-box binding protein (TBP) - regulate the level of
transcription. It currently appears that these interactions are the most
important elements of basal and Tat-activated transcription from the HIV
LTR; other elements of the LTR modulate transcription but do not seem
essential.
2. Role of Tat and TAR
Once integrated into the host cell genome, HIV remains
transcriptionally dormant within the host cell genome for a long but variable
"latent period"; this dormancy is due in large part to the low level of
transcription of the provirus (McCune, 1995). What accounts for the sudden
increase in transcriptional activity which is eventually seen? Cellular
transcription factors binding to the LTR, discussed above, are strongly induced
by T-cell activation, and this global stimulus of HIV-infected cells is probably
crucial in HIV transcription (Levy, 1993). However, even in activated T-cells,
Tat is required for transcriptional upregulation, accounting for its
indispensability in viral replication.
As mentioned earlier. Tat does not bind to DNA, as do conventional
transcriptional activators (Ptashne, 1988). Activated transcription of HIV
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depends on the interaction of Tat with a structured RNA element at the 5'
end of all viral transcripts (Rosen et al., 1985). This is called the TAR (for
Trans-Activation Response) element (Feng and Holland, 1988) (see Figure 2).
TAR RNA is a stem-loop structure located between nucleotides 1 and 59 of all
HIV transcripts. It is extremely stable, with a AG of greater than -50 kcal mol'l
(Sugimoto et al., 1993) and contains a 3-nucleotide impaired bulge just 5' of a
large terminal loop (Dingwall et al., 1990; Roy et al., 1990).
TAR was initially thought to function as a cis-acting DNA promoter sequence
(Arya et al., 1985). However, transactivation is dependent on both the
position and the orientation of TAR, indicating that it functions as an RNA
element and not at the DNA level (Peterlin et al., 1986; Muesing et al., 1987).
Tat binds in vitro to TAR RNA (Dingwall et al., 1990; Weeks et al., 1990).
Specifically, Tat binds to nucleotides in and around the 3-nucleotide bulge
(Dingwall et al., 1990; Roy et al., 1990).
To date. Tat is the only transcriptional activator known to act via
binding to RNA and not to DNA. DNA promoter elements attract proteins
involved in transcription to the site of transcription; this process is easily
understood (Goodrich et al., 1996). But how does an element of the RNA
transcript itself, by binding to a transactivator, facilitate transcription? Its
position at the 5' end of the HIV transcript places both TAR, and Tat protein
bound to it, near to the transcription complex - presumably near enough to
alter its properties in a manner similar to factors recruited via DNA-binding
proteins. Such modulation might involve enhancement of initiation,
elongation, or both, or inhibition of transcriptional termination.
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Although Tat is capable of binding to TAR RNA in vitro, interaction
of Tat and TAR in vivo may require a cellular TAR-binding protein (Hart et
al., 1993; Luo and Peterlin, 1993; Madore and Cullen, 1995). The helical, basepaired portion of TAR seems to serve a structural role; the 3-nucleotide bulge
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Figure 2. The TAR element of HIV-1. This sequence represents nucleotides
1-59 of viral isolate HXB-2(as shown in Arya et al., 1985).

and 6-nucleotide loop regions contain primary sequence determinants
essential for both Tat-TAR binding in vitro and for TAR function in vivo.
The sequence of the loop is also required for intracellular Tat transactivation
(Feng and Holland, 1988; Berkhout and Jeang, 1989; Marciniak et al., 1990a)
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despite the strong likelihood that Tat does not bind there. This requirement
might reflect the binding of another protein - a cellular factor - to this region
of TAR, constraining the sequence variability. A cellular factor binding to the
loop RNA sequence might be a crucial effector of Tat-mediated
transactivation and might itself modulate the activity of the transcription
complex assembled at the HIV promoter.
However, there are arguments against a requirement for a TARbinding cellular factor. A Tat-MS2 fusion protein transactivates transcription
of a reporter transcript containing the MS2 binding site, suggesting that TAR
RNA plays no essential role in transactivation other than to localize Tat to
the promoter (Selby and Peterlin, 1990). This finding also suggests that no
cellular TAR loop-binding factor is necessary for transactivation. Southgate et
al. (1990) obtained similar results, using Rev and the RRE as the heterologous
localization system.

Tat can also function when bound to upstream

promoter sequences via a heterologous DNA-binding domain, rather than by
binding to the nascent transcript via TAR (Southgate and Green, 1991). In
this context. Tat and the acidic activator VP16 effect similar levels of
transcriptional activation. These studies demonstrate that, at least in the
context of reporter systems. Tat transcriptional activation does not absolutely
require TAR or cellular TAR-binding factors.
However, when Tat is localized to the promoter via TAR, the first
59 amino acids of Tat are necessary for function (even apart from the RNAbinding domain) (reviewed by Rosen, 1991). This suggests that the interaction
of Tat and TAR, and the transcriptional activation dependent on their
interaction, cannot be strictly compared with the function of an acidic
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activator like VP16. For example, the TAR sequence may "cripple" the
nascent transcription complex in a manner requiring a cellular factor (which
might bind to Tat or to TAR) for disinhibition. Such an effect would not be
seen when Tat operates at a heterologous promoter lacking TAR.
To summarize. Tat activates transcription when its activation domain
is localized to a promoter by the DNA-binding (or RNA-binding) module of
another protein. This fact, considered independently, suggests that the only
role of TAR (and of the basic domain of Tat, which mediates binding to TAR)
is to direct the activation domain of Tat to the promoter.

Except for the

unusual means by which Tat is bound to the promoter, this model of its
action requires no departure from current concepts of transcriptional
activation.
However, in the setting of Tat-TAR binding in vivo, one or more
cellular TAR-binding proteins may be required for transactivation. Native
Tat function, then, is not strictly comparable to the function of other classes of
transcriptional activators. In particular. Tat transactivation via TAR
localization may involve additional levels of regulation, such as relief of a
transcriptional inhibition engendered by the TAR stem-loop or by an element
of the LTR promoter. I must consider, then, whether Tat interacts with
proteins other than conventional transcription factors (Ptashne, 1988).
E. The mechanism of Tat activation of transcription
The mechanism of Tat-mediated transcriptional activation is not yet
fully understood. A model is still needed which incorporates (1) the action of
cellular transcription factors which bind to the HIV LTR, (2) the contributions
of the TAR element (and cellular TAR-binding proteins), and (3) the action of
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Tat. Does it bind to TAR alone or in cooperation with cellular factors? What
specific interactions account for its transcriptional activation? Most
investigators believe that Tat recruits cellular transcription factors to the
promoter region as do conventional transcription factors. As noted above.
Tat is known to interact with at least two: Spl and TBP (Jeang et al., 1993:
Kashanchi et al., 1994). But it is uncertain how essential these interactions are
to Tat transactivation. Further, it is unclear whether the main effect of Tat is
to increase initiation of transcription, or to promote elongation of
transcription.
Tat increases expression of TAR-linked reporter gene expression at the
level of both RNA and protein; this increase is dependent on the integrity of
both the Tat protein and the TAR element (Peterlin et al., 1986; Hauber et al.,
1987; Muesing et al., 1987). Given that Tat increases transcription from the
HIV LTR in cooperation with cellular factors, is its effect mediated through
increased initiation or enhanced elongation?
The argument for enhanced elongation is based on the premise that
the HIV LTR promoter undergoes transcriptional attenuation or elongates
poorly. Tat may relieve this attenuation or enable elongation (Feinberg et al.,
1991; Laspia et al., 1989). Tat enables RNA polymerase II to elongate through a
termination signal in vivo (Ratnasabapathy et al., 1990). When localized by
placement of TAR RNA into the 5' UTR (Untranslated Region) of c-myc. Tat
directs transcriptional elongation past attenuation sites in the cellular c-myc
gene promoter (Wright et al., 1994). Tat function, in this view, is reminiscent
of the antitermination effected by the phage lambda N protein (Greenblatt et
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al., 1993). Tat may cooperate with cellular proteins which enhance the
processivity of the transcription complex (Kato et al., 1992).
In vitro analysis of Tat transcriptional activation (Marciniak et al., 1990)
demonstrated that the increase in HIV RNA was primarily due to increase in
transcripts longer than 91 nucleotides, suggesting an elongational
enhancement. In cells infected with Tat-defective virus, initiation of
transcription from the LTR proceeds at a high rate, but most transcripts were
less than 300 nucleotides long (Feinberg et al., 1991). In these studies, the sites
of termination are randomly distributed, arguing against the presence of a
specific terminator element. Addition of Tat resulted in marked increase in
distal transcription, while the number was unchanged.
What elements of the LTR, and of the transcription complex assembled
there, are responsible for inefficient elongation? One factor may be the
transcription factor LBP-1. LBP-1 binding to the HIV LTR inhibits elongation
in in vitro assays, and Tat suppresses this effect (Parada et al., 1995). Other
work suggests that transcription throught the stem-loop of TAR is inefficient
without a relieving factor. For example, elongation of HIV transcripts beyond
nucleotide 59 is highly dependent on Tat (Kao et al., 1987; Yankulov et al.,
1994). HIV transcription might, then, be blocked at sequences within the TAR
structure, and Tat might specifically relieve this block. This constitutes a
function of Tat specific for TAR-linked transcriptional activation apart from
increased initiation. Cellular proteins binding to TAR might act at this level
of regulation, either positively or negatively.
In fact, two classes of transcription complex may act at the HIV LTR: a
less-processive complex and a more-processive complex, with the latter
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specifically increased by Tat (Marciniak and Sharp, 1991). Cullen (1993)
postulates a model for Tat-mediated activation of transcription which
potentially reconciles the initiation and elongation camps. He envisions the
presence of two overlapping promoters within the LTR: one with high basal
activity but low processivity (ability to elongate); the other with low basal
activity but is fully process!ve. Tat may increase the number of the latter type,
functioning at the level of initiation but producing increased elongation.
A key prediction of this model is the presence within the LTR of an
active promoter with low processivity. The results of Sheldon et al. (1993)
support this prediction, suggesting that one portion of the LTR (between
nucleotides -5 and +26) induces short transcripts which fail to elongate.
Mutation of this element (termed the 1ST, for Inducer of Short Transcripts)
blocks formation of non-processive complexes but allows Tat transactivation
of processive complexes.
Two separate and overlapping sets of promoter elements specify the
formation of two different types of transcription complexes on the HIV LTR.
One complex, the non-processive type, is formed via the action of the NFkapppa B and Spl sites alone; the other is processive and is dependent on the
TATA box but requires Tat for high levels of transcription (Lu et al., 1993).
These two types of transcription complex may interact; in particular, the Tatactivated, processive complex may require the non-processive complex, in
light of the known importance of the Spl and NF-kappa B sites to Tat
function (reviewed above).
Recent evidence illustrates that Tat transactivation may involve all of
the different elements I have examined: Tat itself, Tat-binding cellular
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proteins, TAR-binding cellular proteins, and the RNA polymerase II-cofactor
complex. Baer et al. (1995) found that a set of cellular proteins modulates the
binding of TRP-185 (a cellular protein which binds to TAR) and also
stimulates the binding of the pol II complex to TAR RNA. They also found
that Tat modified the RNA-binding characteristics of the pol II complex. This
report is among the first to focus on the interactions of Tat, TAR, RNA
polymerase II and cellular proteins binding to all three. Hopefully, future
work will extend these observations and provide insight into the interplay of
the different components involved in HIV transcriptional activation.
F. Tat structure
Most transcriptional activators function by interacting with other
proteins which, when brought near the promoter, increase the activity of the
nascent transcription complex (Ptashne, 1988). If Tat interacts with a cellular
factor required for its transcriptional activation, it is important to learn what
region of Tat mediates this interaction. Knowledge of Tat’s functional
anatomy (see Figure 3) is also important for understanding its non
transcrip tional roles.
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Figure 3. The amino acid sequence and domain structure of HIV-1 Tat. The
amino acid sequence is taken from HIV isolate HXB2 (Arya et al., 1985).
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The 72 amino acids encoded by the first exon of the tat gene are
sufficient for transactivation in mammalian cells; in fact, the first 58 amino
acids are functional, although at a lower level (Seigel et al., 1986). However,
in infected cells, the 86-amino acid form of Tat predominates, and the 72residue form is less abundant (Levy, 1994). Many groups have used this form
of Tat to study its transcriptional function, reasoning that all essential contacts
with cellular factors are mediated within the first 72 amino acids.
The amino-terminal domain of Tat contains several amino acids
critical for function, particularly two glutamate and one aspartate residue
(Rappaport et al., 1989). These acidic constituents may reside within an
amphipathic alpha-helix approximately twelve amino acids long at the Nterminus (Rappaport et al., 1989). This region was once postulated to function
as an acidic transcriptional activator similar to the herpesvirus activator
protein VP16 and the yeast GAL4 protein (Rappaport et al., 1989). However,
disruption of this acidic region lowers but does not eliminate the
transcriptional activity of Tat, suggesting that it contributes to transactivation
but is not essential (Tiley et al., 1990). This would be unusual if Tat were a
typical acidic activator, whose properties entirely depend on the acidic
domain (Hahn, 1993). Also, Tat and VP16 synergistically activate
transcription from the same promoter, implying that they act through
different mechanisms which are additive (Ghosh et al., 1990). Again, this
would be unexpected if Tat were an acidic activator.
The cysteine-rich domain and the core domain are crucial for Tat
function (Carroll et al., 1992) and have collectively been termed the
"activation domain" of Tat.

Separate, single missense mutations of all but
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one of the seven cysteines within the cysteine-rich region completely abolish
function (Ruben et al, 1989; Kuppaswamy et al., 1989; Rice and Carlotti,
1990a).

Overexpression of the ^activation domain,/ inhibits function of full-

length Tat, possibly by competition for cellular factors essential for
transactivation, which may bind to this region of Tat (Carroll et al., 1992).
These cysteine residues appear to mediate metal-linked dimerization of
Tat in vitro (Frankel et al., 1988). Tat does not seem to dimerize in
mammalian cells (Rice and Carlotti, 1990b; Rice and Chan, 1991). However,
incubation of Tat with strong reducing agents drastically inhibits its function,
suggesting that the cysteine-rich region might mediate intramolecular
disulfide bonds important in the tertiary structure of the protein (Koken et al.,
1994). A proposal that this region might constitute a zinc-finger type of DNAbinding domain (Patarca and Haseltine, 1987) has been discarded (e.g., Sadaie
et al., 1990). No specific function has been proven for this essential stretch of
cysteines. However, peptides consisting primarily of the cysteine-rich
domain inhibit transcriptional activation in a non-Tat-specific manner
(Frankel et al., 1989). Therefore, this region likely interacts with a
component(s) of the general transcriptional apparatus and can titrate this
component(s) away from activated transcription complexes in general. This
observation makes the cysteine-rich domain a prime candidate for binding to
critical cellular transcription factors.
The region just beyond the cysteine-rich domain (amino acids 38-49) is
often termed the "core" region (e.g., Carroll et al., 1992). Its sequence is highly
conserved among viral strains and is essential for Tat function. It binds
directly to the human TATA-box binding protein (TBP) in vitro (Kasanchi et
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al., 1994). Tiley et al. (1990) had earlier found that the lysine residue at
position 41 was essential for Tat function; mutation of this residue completely
abrogated in vitro binding of Tat to human TBP (Kasanchi et al., 1994),
suggesting that TBP binding accounts for the essential nature of this lysine
residue.
Most Tat mutagenesis studies indicate that the cysteine-rich and "core"
regions - amino acids 22 through 47 - constitute the minimal activation
domain in transcriptional reporter systems (e.g., Derse et al., 1991). These
amino acids, then, are also likely to bind the cellular factor(s) involved in Tatactivated transcription of HIV; this binding might occur separately from or in
concert with the cysteine-rich domain. A recent study indicates that binding
of TBP is not the only essential function mediated by these amino acids:
certain mutations which abrogate transcriptional activation fail to inhibit
binding of TBP (Wang et al., 1996).
The Tat proteins of both HIV-1 and HIV-2 seem to form homodimers,
but not heterodimers, in the yeast two-hybrid system (Bogerd et al., 1993). The
"core" motif was responsible for this dimerization; the cysteine-rich motif
was not required. I note the possibility, however, that the core and cysteinerich regions of Tat may bind to one or more factors endogenous to yeast cells,
probably components of the transcription complex. The two different Tat
fusion proteins might then interact through a "bridge" factor. None of the
controls employed by Bogerd et al. (1993) would eliminate this possibility.
Dimerization of Tat does not appear to occur in mammalian cells, as
mentioned.
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The basic region of Tat (amino acids 49-58) contains six arginines and
two lysines, mediates RNA-binding and nucleolar localization and is
essential to native Tat function (Ruben et al., 1989; Cochrane et al., 1990a and
1990b; Weeks et al., 1993). However, as mentioned earlier, if the activation
domain of Tat is targeted to the promoter by a heterologous DNA- or RNAbinding domain, the basic domain is dispensible. This fact argues against the
functional significance of Tat's nucleolar localization. The basic domain also
seems to mediate Tat binding to cell surface proteins in a number of studies,
as will be discussed in a later section.
The C-terminal domain of Tat (amino acids 59-72) is dispensible for
activation, although the truncated Tat is somewhat less active in mammalian
cells (Seigel et al., 1986). Tat 1-48 functions as a transactivator in yeast when
targeted to a reporter gene promoter by the GAL4 DNA-binding domain
(Subramanian et al., 1994). Interestingly, Tat 1-72 does not function as a
transcription factor in yeast cells (Subramanian et al., 1994 and results
reported here).
The second exon of Tat (14 amino acids) has also proven dispensible for
transcriptional activity. However, it encodes an RGD peptide which has been
implicated in the binding of extracellular Tat to integrins (Brake et al., 1990;
Vogel et al., 1991). Also, these C-terminal 14 amino acids are necessary for the
Tat-mediated downregulation of MHC class II antigens observed by Howcroft
et al. (1994). Although the 86-amino acid form of Tat is the major form in
HIV-infected cells, the functional significance of the amino acids encoded by
the second exon remains unknown. These residues may act in a nontranscriptional capacity of Tat.
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1. Transdominant Tat mutants
Knowledge of Tat's domain structure has led to development of
several transdominant mutants. A transdominant mutant inhibits function
of the wild-type protein, rather than simply lacking functional ability, as does
a recessive-negative mutant (Herskowitz, 1987). A Tat protein bearing a
disrupted basic domain reduced the amount of RNA produced by wild-type
Tat alone (Pearson et al., 1990). Second-site mutations in either the aminoterminal 23 amino acids or in the cysteine-rich region, eliminated the
transdominant phenotype.

This result supports the hypothesis that these

domains bind to cellular proteins crucial to transactivation. Recall that
peptides corresponding to the cysteine-rich domain of Tat inhibit
transcription globally (Frankel et al., 1986). Another Tat mutant lacking the
entire basic domain was capable of inhibiting the function of the wild-type
transactivator (Modesti et al., 1991).
Two mechanisms for Tat transdominant inhibition are (1) that the
mutant Tat forms inactive complexes with the wild-type, or (2) that the
mutant retains functional domains which sequester cellular factors, making
them unavailable to the wild-type transactivator. Evidence that Tat does not
dimerize in mammalian cells (Rice and Carlotti, 1990b; Rice and Chan, 1991)
suggests that the latter mechanism is more likely.
Several facts stand out from the foregoing survey:
1. The cysteine-rich and core domains must (together or separately)
bind to a component(s) of the transcription complex, most likely including
general transcription factors. This conclusion is supported by functional
mutagenesis studies and by studies of transdominant Tat mutants and Tat
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peptides. Therefore, any search for cellular factors binding to Tat and
mediating its transcriptional properties must focus on this region of Tat.
2. The basic domain of Tat is dispensible if Tat is localized to the
promoter by a heterologous DNA- or RNA-binding protein. This implies
that other properties mediated by the basic domain, such as nucleolar
localization of Tat, are not essential to Tat transactivation. However, the
nucleolar localization of Tat (and of Rev) is incompletely understood and
may have consequences in the HIV-infected cell which are not reflected by
current reporter systems.
Many questions remain regarding the process of Tat-activated
transcription. Some might be answered by identification of proteins which
physically interact with Tat but have not yet been identified, especially in light
of the multiple protein-protein contacts made by many factors involved in
transcriptional regulation (Tjian and Maniatis, 1994; Goodrich et al., 1994).
My two-hybrid search for Tat-binding proteins was an attempt to address this
need.
G. Rev and HIV RNA splicing and expression
Rev binds as a multimer to a structured region present in unspliced
and singly-spliced viral RNAs, called the Rev Response Element (RRE)
(Rosen et al., 1988; Malim et al., 1989a and 1989b; Olsen et al., 1990). This
interaction results in a shift in HIV RNA expression patterns: cytoplasmic
levels of the multiply-spliced transcripts decrease almost to zero, while the
levels of unspliced and singly-spliced transcripts increase dramatically (Kim et
al., 1989). RRE-containing transcripts bound by Rev are physically or
kinetically shunted from the splicing apparatus and transported to the
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cytoplasm (Sodroski et al., 1986), where their translation may be facilitated by
Rev (Arrigo and Chen, 1991; Lawrence et al., 1991). Recent studies indicate
that Rev exerts a direct enhancement on nuclear export of RRE-containing
mRNA (Fischer et al., 1994).
Many investigators have sought to identify cellular factors involved in
Rev transactivation. Candidates include a HeLa cell nuclear factor that binds
in vitro to the same subregion of the RRE that is bound by Rev (Vaishnav et
al., 1991), the nucleolar protein B23, the nuclear envelope (Pfeiffer et al., 1991),
and the translation initiation factor eIF5-alpha (Ruhl et al., 1993). These
interactions have yet to be incorporated into a model of Rev function.
However, Rev's interaction with B23 appears to be coincidental to its
transactivation function, since the basic region (which mediates binding to
B23) can be replaced with a heterologous RNA binding region (Hope et al.,
1990). Interaction with the translation factor eIF5-alpha might explain Rev's
apparent facilitation of HIV RNA translation, but no solid evidence for this
role exists yet.
More recent studies have demonstrated that Rev shuttles between the
nucleus and the cytoplasm (Kalland et al., 1994; Meyer and Malim, 1994) and
interacts with components of the nuclear pore complex (Bogerd et al., 1995;
Stutz et al., 1995) - both properties which aid Rev in facilitating transport of
RRE-containing mRNAs to the cytoplasm. Again, however, the significance
of these interactions is not yet known.
H. Rev structure
As with Tat, the structure of Rev has been analyzed for regions of
distinct functional significance. Rev has been dissected into two separable
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domains (see Figure 4). The basic region (amino acids 35 to 59), consisting
mostly of arginine residues, is responsible for binding to RRE RNA (Cochrane
et al., 1990a) nuclear/nucleolar localization (Cochrane et al., 1990b) and
multimerization (Olsen et al., 1990; Gait and Kam, 1993).
While peptides corresponding to this region can inhibit splicing of RRE-
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Figure 4. The amino acid sequence and domain structure of HIV-1 Rev. The
amino acid sequence is taken from viral isolate HXB2 (Arya et al., 1985).

containing transcripts in vitro (Kjems et al., 1991), this region alone is not
sufficient for Rev activity in vivo (Venkatesh and Chinnadurai, 1990).

As is

the case for Tat, the basic domain of Rev can be replaced by a heterologous
RNA-binding domain capable of targeting the rest of Rev to a reporter gene
transcript (Hope et al., 1990). These findings suggest that Rev function
includes more than inhibition of splicing.
Amino acids 75 to 84 of Rev comprise an essential leucine-rich region
called the activation domain (Malim et al., 1989b). This region seems to
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interact with a cellular factors involved in the enhanced nucleocytoplasmic
transport and/or translation mediated by Rev. Mutations within the
"activation domain" have a transdominant effect in that they strongly inhibit
the function of the wild-type protein (Malim et al., 1989b). The most effective
transdominant mutant of Malim et al. (1989b), M10, creates a missense
mutation in an LE dipeptide at amino acids 78 and 79. Venkatesh and
Chinnadurai (1990) found that mutation of either Leu75 or Leu81 abolished
wild-type function and conferred transdominance on the mutant.
Non-conservative mutations or deletions within the basic domain can
also create transdominant Rev proteins. Kubota et al. (1992) demonstrated
that such a deletion mutant interfered with nuclear localization of the wildtype protein and thereby inhibited Rev function (recall that Rev functions as
a multimer). Transdominant Rev mutants have been adapted to the
inhibition of HIV replication in culture. M10, for example, inhibits HIV
growth in cultured T-cells when transduced into those cells in a retroviral
vector (Bevec et al., 1993).
This work enables us to conclude that:
1. The leucine-rich region of Rev may bind to cellular factors involved
in splicing, nuclear export, and translation.
2. The basic domain is dispensible if replaced by another RNA-binding
domain. However, as with Tat's basic domain, its properties (including
nucleolar localization) are not fully understood, although it has been shown
to bind to B23.
I conducted my initial two-hybrid work with Rev. My specific goal was
to identify cellular proteins that bind to the leucine-rich domain and mediate

30

the post-transcriptional activation effected by Rev. My work was begun prior
to reports that Rev binds to eIF5-alpha and to the nuclear pore complex (Ruhl
et aL, 1993; Bogerd et al., 1995; Stutz et al, 1995).
I. Cellular factors' interaction with Tat
1. Nucleolar protein B23 and its association with Tat and Rev
B23 is an abundant nucleolar protein which shuttles between the
nucleolus and the cytoplasm (Borer et al., 1989) and plays an important role in
ribosomal assembly in the nucleolus (Melese and Xue, 1995). It is known to
bind Rev (Fankhauser et al., 1991) and may also bind Tat (e.g., Marasco et al.,
1994 and results reported here). Its binding to Rev is disrupted by RRE RNA
(Fankhauser et al., 1991), suggesting that the Rev-B23 interaction does not
promote nuclear export of HIV RNA. B23 might instead "recycle" Rev from
the cytoplasm, once it has activated export of RRE-containing RNA.
The basic domain of Rev, which mediates nucleolar localization
(Cochrane et al., 1990b) likely also mediates its interaction with B23. Since
this domain is dispensible for Rev function, B23 interaction is probably
peripheral to Rev function. However, Rev appears to cause nucleolar
dysfunction under certain conditions (Miyazaki et al., 1992), an effect possibly
mediated by its binding to B23. Tat may share this property, since its basic
domain also mediates nucleolar localization (Marasco et al., 1994) and since
my results demonstrate binding between Tat and B23.
2. Cellular Tat-binding proteins
As reviewed earlier, study of Tat suggests that it binds to cellular
proteins crucial for its multiple functions. Several different strategies have
been employed for the identification and cloning of such factors. To date, at
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least six mammalian Tat-binding proteins have been identified; most have
been cloned. Several modulate the transcriptional activation of Tat when
overexpressed or repressed in reporter systems, but it remains uncertain
whether any of them is uniquely responsible for Tat's upregulation of the
HIV promoter.
1. TBP-1 is a novel human protein which decreases Tat-mediated
transactivation (Nelbock et al., 1990). Although it cannot bind to DNA on its
own, this protein strongly activates transcription when localized to a
promoter, as would happen if it interacted with TAR-bound Tat on the
nascent HIV transcript.
2. A protein from human lymphocytes which binds Tat (1-86) on an
affinity column (Desai et al., 1991) enhanced Tat transactivation modestly (Yu
et al., 1995).
3. The activation domain of Tat specifically binds to a protein kinase
activity from human cells (Herrmann and Rice, 1993).

This kinase activity

binds in vitro to the activation domain of Tat but not to functionally-inactive
mutants (Herrmann and Rice, 1995;) it also phosphorylates the carboxylterminal domain of RNA polymerase II, which has been postulated as a
mechanism of Tat-activated transcription.
4. A HeLa cell extract depleted of proteins binding to Tat is incapable of
sustaining Tat transactivation in vitro (Sune and Garcia-Bianco, 1995). This
depletion is not complemented by purified TBP or partially-purified TFIID.
The authors argue that, in addition to interacting with general transcription
factors. Tat must also bind to a "Tat-specific" coactivator.
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5. TAP is a widely-expressed human protein which binds strongly to
Tat on affinity chromatography and which contains a powerful acidic
transcriptional activation domain (Yu et al., 1995a). TAP also binds to the
general transcription factor TFIIB (Yu et al, 1995b), which is known to bind to
acidic activators.
6. Fridell et al. (1995) identified a new human protein, HT2A, which
bound to the "activation domain" of Tat. However, they do not show direct
in vitro interaction of this protein with Tat; it is possible that this protein and
Tat interact indirectly through a yeast factor acting as a "bridge."
7. 8. Tat also binds directly to the "general" transcription factors Spl
(Jeang et al., 1993) and the TATA-box binding component of TFIID
(Kashanchi et al., 1994). These binding events might explain the importance
of both the Spl-binding site and the TATA box in the HIV promoter,
discussed earlier. If Tat contacts one or both factors in the course of
transactivation, it might be necessary for them to already be present in the
transcription complex.
9. A recently-cloned human protein, Tip60, binds to the cysteine-rich
region of Tat (Kamine et al., 1996); this binding was abolished by mutating
either of two cysteine residues within the essential cysteine-rich region
(Kuppaswamy et al., 1989). Overexpression of this protein in transient assays
increased Tat transactivation about four-fold.
Despite this array of Tat-binding proteins, their contributions to Tatactivated transcription are still not clear. I do not know whether any of these
proteins is uniquely required for Tat transactivation. Tat may contact
multiple proteins within the large transcription complex; different
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interactions may result in complexes of varying processivity. Tat may bind
one or several "general" transcription factors; Tat-activated transcription may
require a factor more unique than these (Zhau and Sharp, 1995).
As an illustration of this point. Tat 1-48 "squelches" in vitro
transcription by full-length Tat (Song et al., 1994), apparently by interacting
with "cellular coactivators" required for Tat transactivation but not for
transactivation induced by the acidic activator VP16, which is not squelched
by Tat 1-48. This contention is supported by the identification and partial
purification of a human cellular activity necessary and specific for Tat
transactivation (Zhau and Sharp, 1995). Recall also the evidence from study
of Tat's domain structure and of Tat transdominant mutants: the cysteinerich and core domains are likely to bind cellular transcription factors, either
together or separately. At least one such Tat-binding factor is involved in
general transcription mechanisms, as noted (Frankel et al., 1986). I still do not
understand what cellular factors are essential for Tat transactivation, nor do I
understand how Tat and cellular factors interact to produce activated
transcription from the HIV LTR.
3. Cellular TAR-binding proteins.
It is uncertain whether Tat binds to TAR alone in vivo or whether it
cooperates with cellular proteins. Also, TAR itself may bind to a cellular
protein involved in HIV LTR transactivation. The Tat-TAR complex may
attract a cellular proteins which then mediate the activated level of
transcription required for HIV replication. Alternatively, TAR RNA plus
cellular proteins may collectively represent the target of Tat transcriptional
activation in vivo.
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HIV proviral constructs bearing different TAR mutations display very
different replicative phenotypes despite their similar ability to bind to the Tat
protein in vitro (Harrich et alv 1994). The ability of different TAR sequences
to bind to cellular factors can dramatically affect the growth of virus in vivo.
Cellular proteins which bind TAR might, then, be important in
understanding Tat-mediated transactivation.
A number of mammalian proteins bind to TAR RNA, including three
different HeLa nuclear proteins. TRP-185 (Wu et al, 1991) binds specifically
to TAR loop sequences and cooperates with Tat in activating HIV-1
transcription. It is an attractive candidate for the putative cellular TAR loop
binding factor necessary for in vivo (but not in vitro) binding of Tat to TAR.
TAR binding of a 140 kD HeLa nuclear protein was dependent on both the
primary sequence and the secondary structure of the TAR stem (Rounseville
and Kumar, 1992).

Because the TAR stem contains determinants of short

transcript formation (Sheldon et al., 1993), this protein might be involved in
premature termination of HTV transcripts, a process which might be
overcome by Tat.
Another protein (a ~68 kD nuclear factor) binds to the loop of TAR.
Mutations which prevent its binding also compromise Tat-TAR
transcriptional function (Marciniak et al., 1990b). This protein might
represent the critical TAR loop-binding factor; however, no conclusive
evidence yet exists. In summary, the relevance of cellular TAR-binding
proteins to Tat activation of HIV transcription remains uncertain. As
mentioned, a recent report (Wu-Baer et al., 1995) illustrates the
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comprehensive approach needed for study of HIV transcription and its
several regulatory elements, including TAR.
J. Effects of Tat not related to HIV transcription
1. Tat, TAR and translation
Tat's transcriptional effects are universally acknowledged, although the
mechanism remains disputed. However, Tat's translational effects have not
been conclusively addressed to date. Braddock et al. (1989) reported that Tat
was required for translation of TAR-containing reporter RNA in Xenopus
oocytes. The sequence of the TAR loop was critical for this translational
"activation" (Braddock et al., 1990). Tat does not bind to the loop sequences
of TAR; however, several cellular factors seem to do so, as detailed above.
One of these cellular factors might modulate Tat's translational effects,
particularly if that factor is unique to certain mammalian cell types or to
Xenopus.
The translational activation exerted by Tat might represent relief of
translational inhibition mediated by the HIV leader RNA, including the TAR
region. The HIV leader RNA inhibits translation in reticulocyte lysate, both
in cis and in trans. The trans inhibition is only about three-fold, but a stronger
cis-inhibition (about 50-fold) was exerted by the leader RNA on translation of
a reporter transcript containing it (SenGupta et al., 1990).
TAR itself may modulate translation globally in HIV-infected cells.
TAR RNA inhibits activation of the double-stranded-RNA-activated
inhibitor of translation, DAI, both in vivo and in vitro (Gunnery et al., 1990,
1992). Peptides corresponding to the basic region of Tat can inhibit TARstimulated activation of DAI, apparently by binding to TAR and masking it
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from the kinase (Judware et al., 1993). These results suggest that Tat might
perform a similar function in HIV-infected cells.
However, Tat's translational effects do not appear to be a crucial
element of Tat function. Tat transactivation of HIV RNA in a mammalian
cell reporter system occurs solely at the level of transcription (Laspia et al.,
1989;) no enhancement of translational efficiency was observed. Also, Tat
transactivates HIV DNA, and not HIV RNA, when both are microinjected
into the nucleus of mammalian cells (Chin et al., 1991), indicating again that
the effects of Tat are primarily transcriptional. The results seen in Xenopus
oocytes, then, may be unique to that system. Current understanding does not
support involvement of Tat's translational effects in HIV replication.
2. Tat transactivation of heterologous promoters
Tat protein, exogenous as well as intracellular, can modulate
expression of numerous cellular genes. This effect is usually attributed to
transcriptional effects. For example. Tat increases expression of Tumor
Necrosis Factor IB (TNF-fi) (Sastry et al., 1990) and Transforming Growth
Factor li (TGF-13) (Lotz et al., 1994; Zauli et al., 1992). Tat's induction of TGF-li
might contribute to the immunosuppression seen in AIDS patients and the
immunosuppressive effect of Tat on cultured lymphocytes (Viscidi et
al.,1989).
Tat also increases expression of several extracellular matrix genes in
glial cells (Taylor et al., 1992). This also might result from TGF-fi induction,
since TGF-12 is known to increase expression of several ECM genes. Tat
induction of TNF-alpha (Buonaguro et al., 1992) could in turn activate
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expression of both interleukin 1 (IL-1) and IL-6, effects which have been
ascribed to Tat (Zauli et alv 1993; Gibellini et al., 1994; Scala et alv 1994).
Interestingly, induction of TNF-alpha expression has been linked to Tat-cell
surface binding (Ramazzotti et al., 1996).
Tat decreases IL-4 expression (Link et al., 1992) and induces Ig and IL-6
expression (Rautonen et al., 1994) in monocytes. Tat upregulation of IL-2 in
activated T-cells (Westendorp et al., 1994; Vacca et al., 1994) is at least partly
transcriptional and dependent in part on the NF-kappa B site in the IL-2
promoter. Tat induces expression of both Fibroblast Growth Factor 1 (FGF-1)
and its receptor (Opalenik et al., 1994).
Tat also suppresses expression of manganese-superoxide dismutase
(Mn-SOD), possibly by direct binding of Tat to the Mn-SOD transcript (Flores
et al., 1993). The full-length Tat protein was necessary for both this effect on
the Mn-SOD expression as well as a parallel alteration of the cellular redox
state (Westendorp et al., 1995). Again, this effect might be relevant in HIV
replication and in the T-cell depletion seen in AIDS.
HIV infection (as well as infection by a number of other viruses)
decreases expression of MHC class I genes (Howcroft et al., 1995) via a nine
fold decrease in gene transcription. Tat alone exerts the same repression; and
the two-exon form of Tat was required. This is not true of most studies of
Tat's effects on the expression of cellular genes; most of which employ the
72 amino acid form of Tat. The same group has recently found that this
repression is mediated by Spl-like elements in the MHC class I promoter
(Howcroft et al., 1995). However, another group reports that they could not
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replicate the initial finding that Tat inhibits expression of MHC class I genes
(Matsui et aL, 1996); therefore, this finding must be viewed with caution.
These Tat-mediated derangements of cellular gene expression could
contribute to the immune pathogenesis of AIDS (Levy, 1993). However, these
effects have yet to be demonstrated in the cells of HIV-infected patients; and
their importance to either HIV replication or AIDS pathogenesis remains
speculative.
What are the mechanisms of these effects of Tat on cellular gene
expression? Many of these Tat-mediated alterations in cellular gene
expression may be secondary to an effect of Tat on cellular levels of NF-kappa
B (Demarchi et aL, 1996; Conant et al., 1996). Tat's activation of NF-kappa B
may underlie a number of other downstream effects on expression of other
cellular genes, many of which are regulated by NF-kappa B (e.g., MHC class I,
TNF-alpha, TNF-fi, IL-2, and IL-6). Also, a number of Tat's effects on cellular
phenotype (e.g., apoptosis in lymphocytes) might be due in part to activation
of NF-kappa B. Recent studies in primary human CD4 lymphocytes highlight
the dependence of Tat transactivation on the NF-kappa B sites within the
LTR (Alcami et al., 1995). Regulation of NF-kappa B activity is regulated
primarily by binding of the active subunit (p65) by an inhibitory subunit
(I-kappa B) which retains p65 in the cytoplasm (Liou and Baltimore, 1993).
Tat activation of NF-kappa B, then, might represent relief of this inhibitory
binding, either direct or indirect.
In most cases, the target of Tat modulation in activation of non-HIV,
cellular genes, is undefined. Tat is postulated to bind to the nascent TGF-beta
transcript and to upregulate transcription of that gene in a manner analogous
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to its TAR-mediated effect on HIV transcription (Buonaguro et al., 1994).
However, no physical binding of Tat to the proposed RNA structure has yet
been demonstrated. Given Tat's involvement in transcriptional events, a
transcriptional mechanism for its modulation of cellular gene expression is
plausible. Recent work demonstrates that Tat-mediated transactivation of
TNF-3 transcription synergizes with TAR-dependent Tat activation of the
HIV LTR. However, another potential mechanism is Tat cell-surface binding
and receptor stimulation. This possibility becomes more credible in light of
Tat's known ability to bind to cell membranes, which will be discussed later.
3. Phenotypic effects of Tat expression
Tat is found not only in the nucleus of HIV-infected cells but also in
the cytoplasm. Tat is also shed from infected cells (Heland et al., 1991).
Cytoplasmic and extracellular Tat may exert effects separate from
transcriptional activation. Endogenous Tat (expressed within cells) may exert
not only nuclear effects but also an autocrine/paracrine effect: Tat protein
shed from expressing cells might then bind to a cell surface receptor(s). The
downstream consequences of such receptor binding might account for a
number of Tat's non-nuclear effects.
Expression of HIV-1 Tat in human lymphocytes resulted in an
increased cell growth rate in one study (Caputo et al., 1990) and a slower
growth time and a higher proportion of apoptotic cells in another (Purvis et
al., 1995). The same results were seen with addition of recombinant Tat to
cultured lymphocytes. Exposure to exogenous Tat renders T-cells more
sensitive to T-cell-receptor- and CD4-mediated apoptosis by upregulation of
the cell surface ligand CD95 (Westendorp et al., 1992). The levels of Tat
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necessary for this effect are similar to those found in the sera of HIV-infected
individuals. Li et al. (1995) found that Tat induces cell death by apoptosis in
both cultured T-lymphocytes and in PBMCs from non-HIV-infected donors.
Apoptosis was inhibited by serum and correlated with increased activation of
cyclin-dependent kinases. Tat-mediated sensitivity to apoptosis might, then,
contribute to the CD4+ T-cell loss in AIDS (Levy, 1995), which has yet to be
explained.
Tat-expressing HeLa cells, implanted in nude mice, grow more slowly
and induced less neovascularization than control cells (Huber et al., 1992).
Transgenic mice created by Vogel et al. (1988) expressed Tat primarily in the
skin, rendering these animals useful as a model of AIDS-KS. Many
developed skin lesions which grossly and histologically resembled KS. Some
of the mice later expressed Tat in liver cells; a significant proportion of these
developed hepatocellular carcinoma (Vogel et al., 1991), suggesting that Tat
might play some role in the increased incidence of this tumor in AIDS
patients.
Corallini et al. (1993) derived mice transgenic for Tat expression from a
BK virus vector. Tat was expressed in most tissues of their animals; the most
dramatic phenotype was seen in skin and associated structures. Some
animals remained hairless from birth through two months of age, while
others developed various skin tumors. As observed by Vogel et al. (1991),
most of the mice later developed liver dysplasia, although only one
developed hepatocellular carcinoma. Taken together, these studies
strengthen the hypothesis that Tat plays a role in AIDS-KS and liver dysplasia
in HIV-infected humans (Levy, 1995).
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Frazier and Garcia (1994) repopulated the bone marrow of recipient
mice with cells transduced with a Tat-expressing retroviral vector. Tat was
expressed in all hematopoietic tissues, but no gross abnormalities were seen
in Tat-expressing cells. In contrast, Vellutini et al. (1994) found that many of
their Tat-transgenic mice developed lymphoid hyperplasia in spleen, lymph
nodes and lung. Such hyperplasia is often seen in human AIDS patients.
However, they observed no hyperplasia in CNS or testis, where it is often
seen in human patients.
Recombinant Tat protein activates human endothelial cells (Hofman
et al., 1993), evidenced by increased adhesion molecule expression and
cytokine production. This effect of Tat was synergistic with TNF-alpha. Tat
may serve to increase the permeability of the vasculature in HIV-infected
patients, increasing dissemination of the virus into other tissues. Also, since
KS is postulated to be an endothelial tumor. Tat activation might provide a
critical stimulus for progression to malignancy.
Tat's effects in cell culture and in transgenic animals have not been
explained. Modulation of cellular gene expression is a possible mechanism;
however, is that modulation effected by a direct transcriptional mechanism,
or subsequent to a cell surface-binding event?
4. Other effects of Tat
It is obvious from the foregoing survey that Tat plays a key role in
transcriptional regulation - of HIV and possibly of some cellular genes - and
potentially can regulate translation of HIV RNA. However, there are other
effects of Tat unrelated to HIV gene regulation, some of which might mediate
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the effects of Tat in Tat-expressing cells and Tat-transgenic mice. These
include:
1. Tat binds to the surface of cells.
2. Tat is secreted by infected cells and taken up by neighboring, noninfected cells.
3. Tat exhibits neurotoxicity both in cell culture and via intracerebral
injection.
4. Tat suppresses in vitro antigen-driven lymphocyte proliferation.
5. Tat plays a critical role in Kaposi's Sarcoma progression.
In particular, Tat’s cell-surface binding might be responsible for many of its
other properties, such as modulation of cellular gene expression, induction of
apoptosis, and promotion of Kaposi's Sarcoma. As is true of Tat's
transcriptional action, the identification of Tat-binding proteins might
provide a plausible mechanism(s) for these effects.
1. Tat cell-surface binding.
Several of Tat's non-transcriptional cellular effects may involve the
cell membrane, perhaps via binding to a protein(s) located there. For
example, the RGD sequence encoded by the second exon of Tat may mimic
the RGD peptide found in various molecules of the extracellular matrix
(ECM), where it serves to bind to specific integrin molecules of the cell
membrane (for review, see Yamada and Kleinman, 1992).
Several mammalian cell types attach to culture dishes coated with Tat.
In one study, attachment was specifically dependent on the RGD sequence;
proteins containing single or double conservative mutations of this motif did
not support efficient adhesion (Brake et al., 1990). Small peptides containing
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an RGD sequence inhibited attachment, as did a monoclonal antibody which
recognizes the RGD peptide. These investigators conclude that Tat binds to
cells via an RGD-binding integrin on the cell surface.
However, Vogel et al. (1993) found that the basic domain of Tat, not the
RGD sequence, mediated binding to the vitronectin-binding integrin 3vfi5Synthetic peptides corresponding to the arginine- and lysine-rich region of
Tat supported attachment of rat muscle cells. The same peptide bound to
integrins in cell surface extracts. A similarly basic region of vitronectin
mediated its binding to integrin. Integrin binding of Tat and vitronectin basic
regions was mutually inhibitory, and peptides consisting solely of lysine or
arginine did not bind or inhibit Tat or vitronectin binding.
A 90-kD cell-surface-associated protein, common to several
mammalian cell types, binds to synthetic Tat basic-domain peptides on
affinity columns (Weeks et al., 1993). This protein did not contain the
integrin subunits ay, fil or £4. The investigators suggest the "possibility of
multiple cell recognition sites on Tat and multiple Tat binding proteins/'
which is certainly supported by the findings reviewed here.
Cell surface-binding by the Tat basic domain can be used to deliver
antibody fragments to tumor cells (Anderson et al., 1993). Both cell surface
association and internalization of such fragments was greatly enhanced by
conjugation to Tat (37-62) peptides. Fawell et al. (1994) capitalized upon this
unusual property of Tat to deliver heterologous proteins to both cultured
cells and cells within live mice injected with Tat fusion peptides. Four
different "cargo" proteins conjugated to Tat (amino acids 37-72) efficiently
gained access to the cytoplasm of target cells. This delivery was independent
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of cell type; identical results were obtained with HeLa, COS-1, CHO, H9, NIH
3T3, and primary human keratinocytes and endothelial cells. Likewise, the
basic domain of Tat mediated delivery of an HPV E2 repressor protein to
cultured cells, inhibiting HPV replication and cell growth.
These studies demonstrate the cell-surface binding of Tat (especially the
basic domain) and suggest that Tat itself might provide a method for the
therapuetic delivery of proteins and peptides into cells. However, the key
point is that Tat binding to cell surface proteins might induce signaling
events culminating in one or more of its "pleiotropic" cellular effects.
2. Tat secretion and cellular uptake
Tat is shed from HIV-1 infected cells in culture and can activate the
HIV-1 LTR in neighboring cells (Heland et al., 1991). Extracellular Tat protein,
added to HL3T1 cells in culture, was taken up into the cells and transactivated
the integrated HIV-1 promoter (Frankel and Pabo, 1988). Tat 1-72 gave the
same result. This effect occurs as early as three hours into the co-cultivation
of infected and non-infected cells and at an infected :non-infected cell ratio as
low as 1:1,000 (Marcuzzi et al., 1992). The region of Tat most important for
uptake and transactivation is amino acids 37 through 72, which encompasses
both the basic and core domains. Tat may bind to an unknown cellular
receptor, given its efficient uptake from culture media.
No satisfactory explanation yet exists for Tat's secretion from HIVinfected cells, since it does not contain a signal peptide. Cell lysis is not the
answer; healthy infected cells can secrete Tat without lysis. Tat may belong to
a small group of proteins, including bFGF, which lack a signal sequence yet
can still be secreted into the extracellular space (Mignatti et al., 1992).
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Tat protein has been demonstrated in the serum of HIV-infected
persons. Anti-Tat antibodies are present in the blood of many, if not all, AIDS
patients (Aldovini et al., 1986). These antibodies are present at a pre-AIDS
stage of the disease and may be one factor in the clinical delay of HIV
pathogenesis (Rodman et al., 1993). This unusual property of Tat - its
secretion and cellular uptake - lends itself to the possibility that Tat indeed
may affect gene expression and phenotype in non-infected cells.
3. Tat neurotoxicity
Chemically-synthesized Tat (2-86) bound to synaptosomal membranes
from rat brain, and to rat glioma and mouse neuroblastoma cells, with
moderate affinity (Sabatier et al., 1991). The same peptide induced
depolarization of nerve cell membranes and a decrease in membrane
resistance. Furthermore, it was toxic to both glioma and neuroblastoma cells
and was lethal to mice when injected into cerebral ventricles. These effects
were mediated by the basic region of the Tat peptide. This toxicity may
involve not only direct damage of nerve cell membranes but also immune
activation (i.e., production of cytokines by nearby macrophages or glial cells).
The basic domain of Rev exerts comparable neurotoxicity (Mabrouk et al.,
1991).
Exogenous Tat induces neuronal and astrocytic aggregation (Kolson et
al., 1993). This effect was not lethal and was specific to embryonic brain tissue,
since mature brain cells did not respond to similar treatment. The Tat basic
domain alone was not responsible for these effects; the RGD sequence was
critical to aggregation. These investigators later (Kolson et al., 1994) observed
no toxicity of exogenous Tat on cultured human neuroblastoma cells at
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concentrations similar to those used by Mabrouk et al. (1993) and Hayman et
al. (1993). Differences in the cells used, or in the Tat protein preparations,
may have been responsible for these discrepant results. This group found
that either exogenous Tat or a permanently-transfected Tat gene activated the
HIV-1 LTR in human neuroblastoma cells.
In other hands. Tat influences growth and differentiation of neuronal
cells in a non-toxic manner. PC12 cells, a model system for neuronal
development, grew faster and displayed partial differentiation into neurons
when expressing Tat. Exogenous Tat effected the same increase in
proliferation but had no effect on differentiation (Milani et al., 1993). At
micromolar concentrations, Tat depolarizes the membranes of rat and
human neurons; the same levels of Tat were toxic to fetal neurons in culture
(Magnuson et al., 1995). These effects were localized to Tat amino acids 31-61,
a region encompassing the basic domain. These results constitute additional
support for the neurotoxicity of the basic domain. Tat's cell surface binding
and secretion/uptake properties may be important in its neurotixicity.
4. Tat suppression of antigen-driven lymphocyte proliferation
Tat inhibits proliferation of antigen-stimulated lymphocytes in vitro.
Tat (1-72) inhibited the ability of peripheral blood mononuclear cells (PBMCs)
to proliferate in response to tetanus toxoid or Candida antigens (Viscidi et al.,
1989). This inhibition was concentration-dependent and did not extend to
proliferation in response to mitogens. Hence, gross cytotoxicity was unlikely
to be the mechanism of inhibition. Peptides corresponding to the basic region
of Tat bound to the membrane of lymphocytes in culture and exerted
cytotoxicity on these cells (Benjouad et al., 1993). This effect might be reflected
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in the immune dysfunction seen with HIV infection. Some investigators
report that they cannot replicate these findings (Meyaard et alv 1992).
Tat's immunosuppressive effect on cultured lymphocytes is mediated
(at least in part) by binding to the cell surface molecule dipeptidyl
aminopeptidase type IV, or CD26 (Subramanian et al., 1993). This typifies the
kind of cell surface-Tat interactions which might be involved in nontranscriptional effects of Tat on cells and organisms. Unfortunately, little has
been done to clarify the mechanism of such effects or the relationship with
the apoptotic effect of Tat on lymphocytes (Westendorp et al., 1992; Li et al.,
1995).
5. Tat's critical role in Kaposi's sarcoma
The best-characterized of Tat's extracellular effects, as well as that most
closely linked to human disease, is its role in Kaposi's Sarcoma. KS has
traditionally been found as an indolent angiogenic tumor in skin and other
organs (Gottlieb and Ackerman, 1982). However, the KS associated with AIDS
is more agressive than "classical" KS (Ensoli et al., 1994). This suggests that
HIV infection provides additional growth stimulation to the tumor cells.
Basic FGF (bFGF) plays a key role in the growth of both AIDS-associated
and classical KS (reviewed by Sinkovics, 1991). HIV infection disturbs the
cytokine profile of HIV-infected individuals and thereby favors growth of KS
(Barillari et al., 1992 and 1994; Ensoli et al., 1993 and 1994; Samaniego et al.,
1995). Synergism between Tat and bFGF induces KS growth.
This synergism may reflect Tat's mimicry of some component(s) of the
ECM - possibly the integrin-binding proteins fibronectin and vitronectin.
Recall the study of Vogel et al. (1993), in which Tat and vitronectin both
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supported attachment of cells and were mutually inhibitory in this capacity.
Tat, in picomolar concentrations, stimulates AIDS-KS cells and normal
vascular cells to migrate and to begin a process of endothelial cell
morphogenesis (Albini et al., 1995). The study of Hofman et al. (1993),
demonstrating Tat's activation of endothelial cells, suggests a possible
mechanism for Tat's stimulation of AIDS-KS cells. However, I have yet to
identify specific cellular component through which Tat exerts its angiogenic
effects.
K. A role for Tat in HIV infectivity?
The current list of Tat's non-transcriptional effects may not be
complete. Tat also may play a role in HIV-1 infectivity distinct from its role in
transcriptional enhancement (Huang et al., 1994). Viruses deleted for Tat but
transcriptionally complemented by a heterologous activator lack both
infectivity and cytopathicity compared to TAR(-) viruses, which could not
utilize Tat in transcription but produced it, presumably to act at other points
in the viral life cycle (and to exert such pleiotropic effects as have been
discussed). Since the TAR element is present in viral genomic RNA, Tat
might be a virion-associated protein and function as an infectivity factor.
This possibility is not reflected by current models of Tat's role in HIV
infection, in which it is envisioned exclusively as a transcriptional activator.
Two residues within Tat which are not essential to transcriptional
activity - Ala58 and His62 - are critical for the replicative and cytopathic
properties of an HIV strain recovered sequentially from one infected
individual (Cheng-Meyer et al., 1991). Interpreted in the light of Huang and
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colleagues (1994), this finding suggests that the primary sequence of Tat must
accomodate essential functions unrelated to transcriptional activation.
An HIV Tat deletion mutant produced markedly fewer infectious
particles per replication cycle (Dimitrov et al., 1993). This effect was not due to
a longer replication time and may reflect loss of an infectivity role of the wildtype Tat protein. Antibody to Tat inhibits HIV replication by nearly 50% in
cultured lymphocytes (Steinaa et al., 1994). Tat antibody also inhibits growth
of cell lines permanently expressing Tat (Zauli et al., 1995); this effect is
mirrored by the inverse relationship seen between Tat antibody levels and
HIV antigen levels in the blood of ten HIV-infected hemophiliac patients (Re
et al., 1995). How may I account for this effect, since Tat-mediated
transcriptional activation should not be disturbed by extracellular antibody?
Extracellular Tat may act in a paracrine fashion which would render it
vulnerable to inhibition by an extracellular antibody. This extracellular
function(s) of Tat might be required for optimal levels of HIV replication.
Again, cellular secretion, binding, and uptake of Tat protein may be
important in this paracrine function of Tat.
L. My approach to the study of Tat and Rev
1. Two-hybrid studies
As described in the Introduction, both Tat and Rev appear to bind
cellular proteins crucial to their respective roles in viral activation. Tat also
seems to bind to cellular factors apart from its transcriptional upregulation.
Identification of such cellular proteins would provide a springboard to
investigation of Tat's several effects on HIV transcription and cellular
physiology. To clone such factors, I have utilized the yeast two-hybrid system
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(Fields and Song, 1989), which provides a powerful in vivo method for the
identification of protein-protein interactions (see Figure 5).

The key

advantages of this system over other methods that detect protein-protein
interactions (e.g., affinity columns) are rapidity of large-scale screenings,
availability of the cloned gene after an interaction is found, and occurrence of
the interactions in a eukaryotic, intracellular environment (reviewed by
Allen et al., 1995; Evangelista et al., 1996).
Two-hybrid screening for proteins that interact with Tat does not
depend on the functional activity of Tat within yeast cells. Therefore, this
approach can identify cellular Tat-binding proteins involved in any of several
processes, including but not limited to transcription. I attempted to construct
both Tat and Rev functional systems in yeast. Neither system was successful,
obviating the possibility of genetic searches for yeast or mammalian factors

GAL4 DBD

c
GAL4 DBD

IBP

^Tat

(GAL4 UAS)

2

1

GAL4 AD
^ activated
transcription

B-gaiactosidase reporter gene

Figure 5. The two-hybrid system applied to the study of HIV Tat protein. TBP
= Tat-binding protein; GAL4 DBD = GAL4 DNA-binding domain; GAL4 AD =
GAL4 activation domain.
functionally interacting with Tat and Rev. Another advantage of physical
interaction screening is its power to reveal entirely unexpected associations of
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the proteins under investigation; one is not forced to select in advance the
factors to be probed for involvement. For example, as has been detailed. Tat
and Rev may interfere with cellular functions that are unrelated to their HIV
transactivation functions.
The basis of the two-hybrid system is the creation of two fusion
proteins which stimulate reporter gene expression when they interact Fields
and Song, 1989). One fusion connects the protein of interest (in this case, HIV
Tat or Rev) to the DNA-binding domain of the yeast GAL4 protein (GAL4
DBD). The other fusion tethers either another protein or a library of
sequences to the activation domain of GAL4 (GAL4 AD). Activation of a
GAL4-dependent reporter gene occurs only when the two fusion proteins
bind and reconstitute a functional GAL4 molecule. Two-hybrid studies are
performed in yeast strains deleted for the endogenous GAL4 gene (and also
for the GAL80 gene, which encodes an inhibitor of GAL4). The strains also
contain a GAL4-dependent lacZ reporter gene (and often another, selectable
reporter gene) integrated at a chromosomal site. A yeast colony harboring the
interacting proteins gives a positive signal (C-galactosidase activity or His+
phenotype). The region encoding the interacting protein is sequenced.
The two-hybrid system allows screening for interacting factors encoded
by the genome or transcribed sequences of any desired organism. The
GAL4AD fusion libraries available at the outset of my studies were a yeast
genomic library (Chien et al., 1991) and a mouse embryo cDNA library
(Chevray and Nathans, 1992). The mouse embryo cDNA library was
particularly attractive for my purposes. Screening of this library might reveal
Tat and Rev interactions with factors important in mammalian development
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and perhaps relevant to the severity of HIV effects on pediatric AIDS patients.
Proving the functional significance of an interaction discovered in this
system requires further analysis; an example is demonstration of direct in
vitro peptide binding.
The two-hybrid system has proven useful in analyzing the interactions
of many different proteins. Examples include the yeast SIR (Chien et al., 1991)
and RAP1 (Hardy et al., 1992) proteins, the yeast protein kinase SNF1 (Yang et
al., 1992), the mammalian DNA-binding proteins Eos and Jun (Chevray and
Nathans, 1992), the HIV-1 Gag (Luban et al., 1992 and 1993) and integrase
(Kalpana and Goff, 1993) proteins, the human cell cycle kinase CDK2 (Hannon
et al., 1993), the oncogene products c-myc (Shrivastava et al., 1993) and Ras
(Vojtek et al., 1993), the cytoplasmic domain of the human TNF receptor
(Rothe et al., 1994), the tumor suppressor gene product p53 (Iwabuchi et al.,
1994), and the human thyroid hormone receptor (Lee et al., 1995).
One limitation of the two-hybrid system is that the strength of a given
protein-protein interaction in this system does not necessarily correlate with
the strength of the native interaction. This limitation has been demonstrated
experimentally, using proteins whose binding affinity has been determined
biochemically (Estojak et al., 1995). While two-hybrid interaction strength
usually predicts whether in vitro binding is strong or weak, no linear
relationship exists between two-hybrid signal strength and in vitro binding.
An advantage to my approach is the potential to isolate Tat-binding
proteins from multiple cell types, since I use the mouse embryo cDNA library
of Chevray and Nathans (1992) as my source of candidate factors. Most
investigators searching for Tat-binding proteins have used lymphocyte-
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specific libraries (e.g., Durfee et alv 1993). Tat modulates transcription in non
lymphoid cells in a non-TAR-dependent manner (Taylor et al., 1993); and
extracellular Tat seems to bind to one or more proteins found on the surface
of non-lymphoid cells (Vogel et al., 1993). In view of Tat's pleiotropic effects
on multiple cell types, I desired not to confine my search to lymphocyte
cDNA-encoded candidates.
2. Other studies in yeast
As mentioned earlier, I have constructed other yeast-based systems for
analyzing Tat and Rev gene regulation. One of these systems involves
insertion of the RRE into a reporter mRNA; the activity of the reporterencoded protein could then be quantified with and without Rev expression in
the same yeast cells. Unfortunately, coexpression of Rev did not increase the
activity of the gene product in this system.
Another system, designed to screen for cellular TAR-binding factors,
consists of a reporter mRNA containing the TAR sequence in its 5' UTR.
Translation of this TAR-containing mRNA could be monitored in a genetic
assay for mammalian TAR-binding factors (binding of a protein to the 5' UTR
of most mRNAs drastically inhibits translation). However, basal translation
of the TAR-containing transcript was too low for inhibition to be observed in
large-scale screening.
An additional system takes advantage of the fact that, while Tat (1-72) is
a very poor transcriptional activator in yeast. Tat (1-48) is a moderately potent
activator when targeted to a reporter gene promoter. I have not pursued
investigation with this system, but it remains a potentially useful tool.

CHAPTER TWO
MATERIALS AND METHODS

A. General methods and suppliers
Bacterial and yeast growth protocols and molecular biological
procedures are described in Current Protocols in Molecular Biology (Ausubel
et al., 1995). This manual also lists suppliers of materials used in cloning,
bacterial and yeast culture and other molecular biological applications, my
supplies (e.g., agar, agarose, amino acid dropout supplements, chemicals)
have come from such standard suppliers.

DNA restriction and modification

enzymes were obtained from several different suppliers, including New
England Biolabs, Promega, and Boehringer Mannheim.
B. Bacterial strains and protocols
Escherichia coli strain MC1061 was used for transformation and
production of recombinant plasmids and libraries. The genotype of MC1061 is
F- ara D139 de\(ara -leu) 7696 gal E15 gal K16 del (lac)X7A rpsl (Strr) hsd R2 (rkmk+) mcr A mcr Bl. The calcium chloride protocol (Ausubel et al., 1995) was
used to prepare competent cells, and conditions for storage and
transformation are as described therein. E. coli strain INV-alphaF'
(Invitrogen, Inc.) was used for direct cloning, transformation and preparation
of PCR products; its genotype is end Al, rec Al, hsd R17(r-k, m+k), sup E44,
lambda-, thi -1, gyr A, rel Al, psi 80, lac Z deltaM15delta(Zac ZYA-arg F), deo
R+, F\ Minipreparations of DNA were obtained by the alkaline lysis method
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(Ausubel et al., 1995) or by QIAGEN chromatography as described by the
manufacturer.
C. Yeast strains and protocols
Dr. Pierre Chevray and Dr. Dan Nathans kindly provided the yeast
strain PCY2. Yeast strains GGY1:171 and Y153 (Durfee et al., 1992) were kindly
provided by Dr. Stan Fields, the inventor of the two-hybrid system. Dr. David
Beach kindly provided the two-reporter strain HF7c, which offers the
advantage of very low basal activity of the integrated HIS4 gene and so does
not require the use of the toxin 3-aminotriazole (an inhibitor of HIS4 activity)
in solid media.
Yeast cells were transformed according to three different protocols: the
lithium acetate procedure listed in Ausubel and colleagues (1995), the DMSOlithium acetate procedure of Hill and colleagues (1991), and the BIO-101 Yeast
Transformation Kit (BIO-101, La Jolla, CA). The kit was found to be more
uniformly reliable procedure, justifying its higher cost. Protocols for yeast
DNA and RNA preparation are from Ausubel and colleagues (1995).
D. Two-hybrid plasmids and library
Dr. Fields provided aliquots of the yeast genomic DNA - GAL4AD
fusion libraries YL1, YL2, and YL3, as well as the vectors pMA424 and
pGADlO. Drs. Chevray and Nathans provided the plasmids pPC62, pPC76,
pPC79 and pPC86, and an aliquot of the mouse embryo cDNA - GAL4AD
fusion library pPC62 (Chevray and Nathans, 1992).
This library was amplified by electroporating the E. coli strain MC1061
with a small aliquot of library DNA, spreading the transformants onto twenty
LB-Amp plates to obtain very densely-packed but discrete colonies, and
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isolating DNA after pooling all transformants in a large-scale CsCl plasmid
DNA preparation (Ausubel et aL, 1995). Plating is necessary to prevent
outgrowth of plasmids containing small inserts and loss of plasmids with
large or toxic inserts during liquid culture.
E. Oligonucleotides
Oligonucleotides were synthesized on four different synthesizers: an
Applied Biosystems machine at the City of Hope core facility (supervised by
Dr. Bruce Kaplan and Dr. Piotr Swiderski), a Cruachem machine run by the
Rossi lab (under the supervision of Dr. James Deshler, then a postdoctoral
fellow), an Applied Biosystems PCR-Mate in the Rossi lab (which was
operated by several lab members), and a larger Applied Biosystems machine
owned by Loma Linda University (supervised by Dr. Garry Larson).
Some oligonucleotides were prepared by a rapid precipitation
technique (adapted for my purposes by Dr. James Deshler): 100 microliters of
the deprotected oligo (in concentrated ammonium hydroxide, cooled on ice
subsequent to deprotection) was added to one milliliter of sec-butanol. The
mixture was vortexed for fifteen seconds and spun in a high-speed
microcentrifuge for at least fifteen minutes. The precipitate is dried and
resuspended, and absorbance is measured at 260 and 280 nanometers to
determine amount and purity of the oligo.
Other oligonucleotides were treated in the standard manner: after
complete drying of the ammonium hydroxide suspension, the deprotected
oligo is resuspended in water or buffer and the concentration determined as
described above.
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F. Polymerase chain reaction (PCR)
1. Materials
The polymerase chain reaction (PCR), and several useful variants,
provided a rapid and convenient method for adapting existing sequences to
my purposes, as well as obtaining novel sequences (e.g., the 5' spurious PCR
used to clone 5' extensions of cDNAs encoding Tat-interacting proteins, as
reported by Struck and Collins, 1994). The heat-stable polymerase used in all
reactions was the Vent (exo") DNA polymerase (New England Bioloabs,
Beverly, MA) because of its higher fidelity and greater thermal resistance
compared to Taq polymerase. The buffer provided by the manufacturer with
the Vent polymerase was used (10 mM KC1, 20 mM Tris-HCl, 10 mM
(NH4)S04, 2 mM MgSC>4, 0.1% Triton X-100).
2. Standard PCR parameters
Standard PCR parameters are: 30-60 seconds denaturing at 95° C; 30-60
seconds annealing (temperature dependent on oligonucleotide composition
but ranges from 45-55° C); 30-120 seconds extension at 72° C. Standard PCR
comprises 25-30 cycles of the above parameters, with an optional final
extension cycle of 5 minutes at 72° C.
3. ’’Spurious PCR" parameters
"Spurious PCR" parameters (Struck and Collins, 1994) differ from the
standard PCR in that the annealing temperature used in the first (non-nested)
PCR is often lower than that used in a standard PCR (down to 40° C).
However, this is not always necessary; in my hands, use of HIV sequencederived primers did not require low annealing temperatures. Annealing
temperatures used with these primers ranged from 50-55° C. (As mentioned
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later, these HIV primers would not be expected to bind stringently to mouse
cDNA sequences). Annealing temperature should be adjusted for each set of
spurious primers used; success may be guaged by a relative paucity of bands
on agarose separation of the first PCR reaction, with bands becoming visible
on separation of the second, nested reaction (when specific priming events
are preferentially amplified). Extension times are longer with spurious PCR:
three minutes is adequate for most purposes.
4. Gene construction by PCR: Rev expression constructs
Both the full-length and the truncated Rev gene were constructed by
PCR //fill-in,, of overlapping oligonucleotides (Dillon and Rosen, 1990); eight
overlapping 85-mer oligonucleotides were used to construct the gene. I used
this approach (rather than simply amplifying the native Rev sequence from
HIV DNA) to introduce codons optimal for protein production in yeast cells.
Since I initially wanted to recapitulate Rev function in yeast, a high level of
Rev protein might have been required. The source of the preferred yeast
codons was Bennetzen and Hall (1982). The sequence of the Rev constructs
was verified by cloning of the PCR products into the Bluescript vector and
dideoxynucleotide chain-termination sequencing by the Sequenase procedure
(U.S. Biochemicals, Cleveland, Ohio).
The truncated Rev gene lacks the amino-terminal basic domain and
consists of amino acids 61 to 116. Both constructs were cloned in Bluescript
and sequenced, then subcloned into the appropriate fusion vectors. The use
of overlapping oligonucleotides gave many mutations during PCR, especially
with the Taq polymerase. However, the Vent polymerase (New England
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Biolabs) was much less error-prone in the context of overlapping oligos. Use
of this enzyme generated clones free of mutations.
The synthetic downstream promoter designed for the Rev gene was
adapted from the work of several groups. Pertinent references are Dobson
and colleages (1982), Hahn and colleagues (1985), and Munholland and
colleagues (1990). The termination and polyadenylation signals were adapted
from the work of Russo et al. (1991) and Proudfoot (1991). The sequence of
the downstream promoter elements is as follows:
TTTCCACAACATATAAGTAAGATTAGATATGGATATGTATATGGATAT
GTAT ATGGTGGTAATGCC AATTTTTGA AAATTC AATATA. The sequence
of the termination and polyadenylation signals is as follows:
TTTATTTTTTTATAGTTATGTTAGTATTAAGAACGTTATTTATATTTCA
AATTTTTCTTTAGCTGCGGCCGCAGCTAG.
5. Gene construction by PCR: Tat expression constructs
The tat genes used in these studies were amplified directly from the
plasmid HIV-HXB2. This is Bluescript containing the proviral sequence
HXB2 but lacking the LTRs; it is not considered hazardous, as are full-length
DNA copies of the HIV genome. The tat (1-72) and tat (1-48) PCR products
were cloned in Bluescript and sequenced by the Sequenase procedure (U.S.
Biochemical).
Later, an oligonucleotide was designed to amplify a tat gene encoding
amino acids 1 through 86 (the oligonucelotide represents a new 3' primer
containing the additional 42 nucleotides of the second exon of tat, allowing
PCR to generate a full-length tat gene). Another oligonucleotide hybridizing
to the region of the tat gene encoding amino acids 49 through 56 enabled us
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to amplify and clone a tat gene encoding amino acids 49 through 72, which
represents primarily the basic domain.
G. Development of functional yeast Tat and Rev expression systems
I attempted to construct a yeast system to recapitulate the function of
Rev and the RRE. I amplified the RRE sequence from pBKBHIOs (234
nucleotides) using primers which attached an Ndel site to each side of the
RRE. I would like to note, for the benefit of anyone amplifying such a
structured piece of DNA, that I had difficulty obtaining a non-mutated PCR
fragment of the RRE. A higher annealing temperature during the reaction
might have ameliorated this difficulty.
The TAR sequence utilized in the Tat-TAR yeast functional system
corresponds to nucleotides 1 through 59 of HIV-1. It was amplified from
pBKBHIOs. I attached a PstI site to each end in order to clone the TAR
sequence into the lacZ reporter gene in the plasmid pRP557 (generously
provided by Dr. Roy Parker).
H. Yeast two-hybrid procedures
1. Use of one-reporter yeast strains
Yeast cells are separately transformed with the two vectors (based on
pPC62 and pPC86, which contain the selectable markers LEU2 and TRP3,
respectively). The yeast strains used in my experiments lack functional copies
of these genes and require them for growth. Selective plating of
transformants on media lacking leucine and tryptophan allows the growth of
double-transformants only. When a given yeast cell harbors two fusion
proteins which physically interact, the integrated reporter gene(s) is
transcribed, yielding B-galactosidase or His+ signal, or both, as described
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below. Single-reporter yeast strains contain only one of these reporter genes
and the manipulations necessary in such strains take weeks to months to
perform, primarily due to variable success in transforming bacteria with
crude yeast DNA lysate.
2. Assay of fi-galactosidase activity
li-galactosidase activity is assayed as follows: colonies are grown and
transferred to supported nitrocellulose membranes (Schleicher and Schuller,
Cleveland, OH). Colonies are lysed and proteins fixed to the membrane by
immersion in liquid nitrogen. £-galactosidase activity is demonstrated by
incubation of the membranes on filter paper saturated with the substrate Xgal, which turns blue when cleaved by 6-galactosidase. X-gal is dissolved as a
100X stock at lOOmg per ml in N,N-dimethylformamide and added to Z-buffer
immediately prior to use. Z-buffer is: 60 mM Na2HP04, 40 mM NaH2P04, 10
mM KC1, and 1 mM MgS04. 2-mercaptoethanol is added to a final
concentration of 40 mM immediately before use. Z-buffer is not autoclaved.
A 1+ to 6+ scale of fi-galactosidase activity reflects the results of colony
lift assay, with 1+ the weakest of detectable signals and 6+ the strongest.
Colonies are considered 6+ if a blue color is obvious within fifteen minutes of
incubation at 37° C with X-gal. 5+ denotes blue within one hour; 4+, blue in
2-4 hours; 3+, blue in 6-12 hours. 2+ colonies are blue in 12-24 hours, and 1+
colonies, the weakest, turn blue in 24-48 hours.
3. Assay of HISS activity
Activation of the HISS reporter gene is assessed by the rapid relative
growth of colonies harboring interacting fusion proteins. Such colonies grow
to visible size in 2-3 days, whereas background colonies require five days to
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become clearly visible. Growth of the yeast Y153 for colony selection by the
His+ phenotype is on medium containing 25 mM 3-aminotriazole (3-AT),
which is toxic and which inhibits activity of the HIS3 gene product. 3-AT is
dissolved in water at 2.3 grams, in 50 mL, per liter of media. This solution is
filter-sterilized and added to autoclaved media prior to pouring of Petri plates.
Plasmid DNA is isolated from colonies that generate fi-galactosidase
activity and is sequenced to reveal the identity of the interacting factor.
I initially worked with the single-reporter strain PCY2 and identified
over twenty different candidate Rev-interacting factors. However, after the
lengthy procedure (unique to the single-reporter system) of testing for Rev
specificity of the interactions, no true positives remained. Subsequent
screenings with the newly-developed two-reporter strain Y153 revealed many
false positives which were more quickly removed from consideration. Again
no true Rev-interacting clones were identified.
4. Use of two-reporter gene yeast strains
The basic procedure used in two-hybrid screening and analysis, in tworeporter strains, is as follows: those colonies displaying a His+ phenotype
grow more rapidly on media lacking histidine and therefore contain a
potential interacting pair of proteins. These colonies were restreaked on solid
complete synthetic medium lacking histidine, leucine, and tryptophan and
with 3-aminotriazole added (CSM-HIS-LEU-TRP/3-AT). Both the HIS+ and
fi-galactosidase signals were confirmed. This procedure requires only days to
perform.
Single colonies were picked and grown in liquid complete synthetic •
medium lacking tryptophan (CSM-TRP) to select for the cDNA library
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plasmid. A 1.5 mL aliquot of each liquid culture was used to isolate plasmid
DNA from the yeast cells (as detailed in Ausubel et al., 1995). Aliquots of 5-10
microliters of each crude plasmid lysate was used to transform E. coli MC1061
by standard calcium chloride procedure (Ausubel et al., 1995).
Several clones from each transformation were picked, grown in LBAmp liquid media, and minipreparations of plasmid DNA were obtained
either by the alkaline lysis procedure (Ausubel et al., 1995) or by QIAGEN
chromatography performed according to the manufacturer's instructions.
The plasmid DNAs were digested with Hindlll to identify the cDNAGAL4AD plasmids.
Inserts were removed from the cDNA-GAL4AD plasmids with SallNotl double restriction digest, cloned in Bluescript, and sequenced. Some
cDNA sequences were also obtained (usually with lesser quality) by direct
sequencing of the yeast plasmid with an oligonucleotide complementary to
the GAL4 activation domain.
I. DNA sequencing and sequence analysis
Sequencing of the Rev constructs (with the synthetic downstream
promoter and the termination/polyadenylation signals) and the actin UAS
(Upstream Activating Sequence - the yeast equivalent of a mammalian
enhancer element) was carried out manually, using the US Biochemical
Sequenase 2.0 Kit. Later sequencing of the Tat and TAR constucts, and the
many two-hybrid library clones isolated as (false-positive) Rev interactors and
as Tat interactors, was done by automated sequencing facilities at both the City
of Hope (by Hector Rivera) and at Loma Linda University (by Dr. Garry
Larson).
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Sequences of all Tat- and Rev-interacting cDNAs were compared
against the GENBANK database in one of two ways. First, the nucleotide
sequences (from both the 5' and the 3' end of the cDNA inserts) were analyzed
for homology with known sequences using the DNASTAR software
(DNASTAR Inc., Madison, WI). Secondly, the sequences were sent via the
Internet directly to the National Center for Biotechnology Information and
compared against known sequences using either the BLASTN or the BLASTX
programs. The latter program translates all six reading frames of the
sequence given to it and compares these against known protein sequences.
The most recent comparison of sequences was performed during August 1996;
several new homologies discovered at this time are recorded in the
Appendix.
J. 5' cloning procedures
An important objective of these studies was procurement of complete
cDNA sequences of Tat-interacting proteins; however, many of the fragments
encoding Tat-interacting proteins were incomplete. No library was available
which was likely to contain complete copies of the longer (> 2.5 kB) cDNAs.
For the cloning of 5' extensions of cDNAs encoding Tat-interacting proteins,
two strategies were employed. First, an aliquot of the mouse embryo cDNA
library from which it was originally obtained (Chevray and Nathans, 1992)
was subjected to PCR, searching for a sequence with more 5' sequence than
the original clone. Sequences of the 5’ and 3' primers used for this procedure
were derived from vector (pPC62) and cDNA sequences, respectively. (The 5'
vector primer is complementary to the sequence of the GAL4 activation
domain). This worked once, yielding about 650 additional nucleotides.
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Further PCR extensions of the library DNA failed, probably indicating that no
longer 5' clone existed in the library.
I then employed the "spurious-priming" technique described by Struck
and Collins (1994) (Figure 6). My substrate for these reactions was randomhexamer-primed cDNA from total RNA of 13.5-day mouse embryos (kindly
provided by Dr. Jeff Mann of the City of Hope). This strategy worked well,
allowing us to obtain more 5' sequence in steps ranging from 80 nucleotides
to about 400 nucleotides.
In brief, this procedure entails the use of any available oligo for the 5'
priming event. This spurious primer binds with low efficiency at many sites
(not just within the 5' cDNA sequence desired) in the first reaction. The
second round of PCR enables specific amplification of the desired
cDNA by virtue of the nested oligo designed from the last piece of known
sequence. I placed a Notl site at the 3' end of the nested primer. All of these
PCR products were double-digested (with Sail and Notl), purified on
agarose gels and then cloned and sequenced in Bluescript. The resulting
sequence information was compared against the GENBANK database.
The final extension step did not yield to the method of Struck and
Collins (1994), despite multiple attempts to clone the 5' 42 nucleotides of
coding sequence (and 5' UTR sequence) from both random-primed cDNA and
from mouse genomic DNA. I then used the RACE technique, which utilizes
T4 RNA ligase to attach an "anchor" oligonucleotide to the 5' end of the
extended cDNA (Frohman et al., 1988). The anchor sequence provides an
annealing site for a primer used in subsequent PCR amplification of the
cDNA. Using two different sets of nested primers, two fragments were
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isolated which represented the 5' end of the clone 7 cDNA, including the
5' 14 codons and the 5' UTR.

"spurious" 5' primer
(binds aberrantly)

3' primer 1

ROUND 1

unknown 5' sequence of cDNA

known 3'sequence

3

extremely low yield of PCR product 1, not visible on agarose gel
may be multiple PCR products in round 1

"spurious" 5' primer
(now binds specifically to PCR product 1)

ROUND 2

unknown 5' sequence of cDNA

3' primer 2 (nested)

known 3'sequence

greater yield of PCR product 2, visible on agarose gel
may be multiple PCR products in round 2

Clone and sequence; twenty extra nucleotides
of known 3' sequence allows confirmation
of correct sequence (specific 3' priming).
Figure 6. The "spurious PCR" technique of Struck and Collins (1994).

K. 6-His-tagged protein procedures
The QIAEXPRESS system (QIAGEN) tags the protein to be purified
with six histidine residues, allowing the rapid isolation of the tagged peptide
on nickel columns or resin and the elimination of all but a very small
proportion of extraneous bacterial protein. Using the rapid small-scale
procedure described in the QIAEXPRESS manual, I obtained high levels of
expression of Tat (1-72), Tat (1-48), and Tat (49-72). It was more difficult to
produce and isolate the clone 7 peptide; larger bacterial pellets were required
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to yield less purified protein. One possible explanation for this paucity of
clone 7 protein is the much larger size compared to the short Tat peptides (the
clone 7 fragment expressed in this system is about 300 amino acids). B23
protein was produced to high quantity in this system, expressed from vectors
containing B23 genes constructed by PCR amplification from the B23 clones
isolated in Tat two-hybrid screening.
Purification in non-denaturing solvents would be optimal for use of
peptides in interaction studies. I tried the QIAGEN non-denaturing
purification procedure but had little success in obtaining sufficient quantities
of the peptides.

CHAPTER THREE
RESULTS

A. Two-hybrid studies of Rev
As detailed in the Introduction, Rev multimerizes during its posttranscriptional activation of HIV-1 gene expression (Olsen et al., 1990). It also
appears to bind to cellular factors (through its leucine-rich activation domain)
which are involved in its function (Malim et al., 1989; Hope et al., 1990). The
two-hybrid system offered a means of both demonstrating and analyzing
intracellular Rev dimerization and screening for cellular proteins which bind
to Rev. Therefore, I cloned both a full-length and a truncated Rev gene into
two-hybrid plasmids fusing the Rev protein to the GAL4DBD and to the
GAL4AD.
1. Screening for Rev-Rev interaction in a one-reporter strain
I first examined the ability of Rev-GAL4DBD and Rev-GAL4AD
constructs to interact with each other in the GGY1:171 strain. My intention
was to learn whether the oligomerization of Rev, known to occur in
mammalian cells (Olsen et al., 1990), would mediate activation of the GAL4dependent reporter gene via Rev-Rev interactions inside yeast cells. If such
an interaction were reproducible in the two-hybrid assay, it would serve as a
useful system for genetic analysis and inhibitor screening.
Colony lift and X-gal incubation of reporter colonies repeatedly showed
no 6-galactosidase signal (no interaction) in yeast colonies bearing both RevGAL4DBD and Rev-GAL4AD fusion proteins. Filters were incubated in X-gal
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substrate for two days at 37° C to detect weak signal, but Rev-Rev colonies
were identical in color to control colonies bearing only one Rev plasmid.
This lack of Rev-Rev dimerization in the yeast two-hybrid system echoes the
results of Bogerd et al. (1993), who similarly failed to demonstrate such
interaction.
Since Rev is known to multimerize in mammalian cells, I must
account for the lack of signal observed with the yeast two-hybrid system.
These negative results might be due to the strong nucleolar localization
signal of the Rev protein (the basic domain). This region might strongly
localize Rev fusion proteins to the dense crescent (the yeast equivalent of the
nucleolus) and prevent reconstitution of a GAL4 activator in the nonnucleolar region of the nucleus, where the reporter gene would be
transcribed.
Therefore, I created GAL4AD and GAL4DBD fusions with a truncated
version of Rev retaining the "activation sequence" but lacking the basic
domain which localizes Rev to the nucleolus. This domain is likely to
mediate Rev interaction with a cellular factor(s) (Hope et al., 1990). This Rev
peptide does not multimerize, since the basic domain is responsible for this
property; but it has the potential to reveal the cellular factor(s) involved in
Rev transactivation by screening two-hybrid libraries for interacting proteins.
The truncated peptide, as mentioned, obviates the possible aberrant
localization of the fusion protein to the dense crescent.
2. Screening for Rev interactions in a one-reporter strain
I conducted multiple large-scale screenings for interactions of libraryencoded factors with both the full-length and the truncated Rev constructs.
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Of approximately 500,000 colonies analyzed for reporter gene activation in
five separate assays, none yielded true Rev interactors, as was eventually
revealed in rescreening experiments.
Studies with the Rev-GAL4 DNA-binding domain (GAL4-DBD)
plasmid were initially carried out in the yeast strain PCY2 (Chevray and
Nathans, 1992), which contains a single reporter gene (GAL UAS-lacZ).
Twenty colonies were identified which gave a S-galactosidase signal in this
strain (from about 400,000 colonies). An initial signal in a one-reporter strain
may result from (among other things) weak binding of the library-encoded
cDNA-GAL4AD fusion protein to the reporter gene promoter, yielding a
false-positive interaction. These interactions are detected by isolating the
library-encoded factor and testing it for lack of signal with a heterologous
GAL4DBD fusion protein. If the library fusion protein gives signal with a
non-Rev GAL4DBD fusion protein, it does not bind specifically to Rev and is
a false-positive.
While determining the validity of the twenty initial interactions, I
chose clone 34A (the cDNA library plasmid isolated from one of the twenty
potential Rev-interactor-containing colonies) for further study. The Sall-Notl
cDNA fragment of this clone was subcloned into Bluescript and sequenced.
Its homology to a bacterial membrane protein, htrB (Figure 7) led us to
speculate that this protein might be a novel component of the nuclear
membrane - a logical site for Rev interaction, since it enhances
nucleocytoplasmic transport of RRE-containing mRNA. This cDNA
corresponds to a single-copy gene in the mouse (see Figure 8). The
coresponding mRNA was about 1500 nucleotides long (Figure 9).
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Unfortunately, all of the //Rev-interacting,/ clones isolated in my
screening experiments, including 34A, were false positives. All of the cDNAGAL4AD fusion proteins activated the reporter gene in a non-Rev-dependent
manner and therefore do not bind specifically to Rev. Several control
plasmids were used to confirm this lack of Rev specificity, including pMA424
without an insert and pMA424 bearing various heterologous protein fusions
(e.g., Fos-GAL4DBD and Jun-GAL4DBD).
I learned that working with a one-reporter strain entails much longer
delays between initial identification of candidate interactors and elimination
of false positives. This delay is due to the need to isolate the library plasmid,
transform it into yeast bearing several control plasmids, and assess 6galactosidase signal from these colonies when they have grown. As will be
appreciated in following sections, a two-reporter strain speeds the process of
false-positive elimination.
3. Screening for Rev interactions in a two-reporter strain
The two-reporter-gene strain Y153 was employed for screening with the
Rev-GAL4DBD construct. The full-length and truncated Rev genes were
subcloned into the plasmid PC62, a GAL4AD fusion plasmid allowing
selection with the LEU2 marker (necessary for use in this yeast strain).
Approximately 300,000 colonies were screened with both Rev fusion
constructs; twelve colonies exhibited activation of the HIS4 reporter gene
(observed as more rapid growth of these colonies). However, none of these
constructs activated the B-galactosidase gene, indicating that all were false
positives. None of these clones were sequenced.
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The Rev two-hybrid project was extended to screening of the yeast
genomic library. This approach is being conducted by others in the Rossi
laboratory and has demonstrated Rev interaction with several yeast
nucleoporin proteins (L. Scherer and J. Francis, unpublished results).
B. The nature of false positives in the two-hybrid system
All twenty clones isolated in the initial Rev screening were false
positives; subsequent screening of 300,000 colonies in the two-reporter strain
yielded no specific interactions of Rev with library-encoded clones. The
reason for this is unclear. It is possible that the mammalian protein(s) which
bind to Rev during the course of its transactivation are unable to do so within
yeast cells. Alternatively, the mouse embryo cDNA library may not include a
member which encodes an effective Rev-binding protein(s), either due to lack
of a necessary full-length clone or to lack (or scarcity) of such a factor in the
cells of mouse embryo. Rev functions in murine cells, however (Murphy et
al., 1993). Therefore, it is unlikely that there is no mouse homolog for the
human Rev-binding factor(s).
Several classes of false positives are possible in the two-hybrid system
(Bartel et al., 1993). These include: (1) clones which bind to the downstream
promoter DNA, and (2) clones which bind to the GAL4 DNA-binding domain
itself. The authors indicate that, in their experience, examining the ability of
the candidate clone to activate transcription with several irrelevant
GAL4DBD fusions will serve to eliminate all such false positives. Use of a
two-reporter yeast strain (whose reporter genes bear different promoter
sequences) will eliminate false positives except for proteins which bind to the
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GAL4 DBD. Such a protein is theoretically possible but has not been reported
as a source of false-positives in the two-hybrid system (e.g., Bartel et al., 1993).
C. Two-hybrid screening for Tat-interacting cellular factors
Tat effects a crucial transcriptional activation of the HIV LTR, and
knowledge of its mechanism might offer new therapeutic avenues in the
treatment of HIV-infected patients. Tat also is capable of other activities
which seem unrelated to its transcriptional role, including its release from
HIV-infected cells, uptake by neighboring cells, and phenotypic effects on
various cell types. I have reviewed evidence for Tat's interactions with one
or several cellular factors. These include transcription factors, cell surface
proteins, and possibly translation factors and proteins involved in regulation
of cell growth and death.
Other groups have searched for lymphocyte-specific Tat-binding factors,
using the two-hybrid system as well as other methods, my screening of the
mouse embryo cDNA library has the potential to reveal interactions of Tat
with proteins from multiple cell types. Tat can transactivate transcription in
rodent cells as well as in human cells (e.g., Cullen, 1986; Murphy et al., 1993;
Sutton et al., 1995). Hence, I believe I was justified in using the available
mouse library to search for Tat-binding factors involved in its transcriptional
activation.
It was important for my studies that Tat 1-72 does not activate
transcription in yeast, since even weak activation might have obscured signal
from interaction of Tat with a cDNA-GAL4AD fusion protein. I first
determined that the Tat 1-72-GAL4DBD consruct did not activate
transcription of the reporter genes. I then screened more than 10^ colonies
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with the Tat 1-72 GAL4DBD fusion plasmid, in ten separate large-scale
screening experiments. More than one hundred colonies demonstrated
activation of the HIS4 reporter gene. Of these colonies, more than thirty also
gave S-galactosidase signal on restreak and colony lift; these were further
characterized as true Tat-interactors. Library inserts were subcloned from the
parent plasmid into Bluescript vectors and sequenced. Sequence analysis was
performed with DNASTAR homology searches and with the BLAST program
of the National Center for Biotechnology Information (available via Internet).
I have identified a total of twenty-two separate cDNAs from the mouse
embryo library which show interaction with Tat. This number is far in excess
of what I expected and desired. While I believe that several of my clones are
informative regarding cellular (and possibly extracellular) functions of Tat, I
also believe that the number of "Tat-interacting" proteins discovered by this
screen reflects also (1) the propensity of the Tat protein to bind to a number of
different types of proteins, and (2) the possibility that Tat binds to a yeast
protein(s) which allows "bridging" interactions with several types of cDNA
library-encoded fusion proteins. Both of these possibilities will be discussed at
greater length.
However, I was faced with another, immediate problem: the choice of a
single clone for follow-up experiments. I chose clone 7 (isolated three times)
for further work, for reasons which will be discussed. Sequence information
and homology analysis of the twenty-two different Tat-interacting clones is
presented in Table 1.
The tumor supressor protein p53 was isolated and fits into two categories:
it is a transcription factor and also contains a proline-rich region. I have dealt
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extensively with only one of these categories: the EGF-like repeat-containing
proteins, particularly the novel gene product encoded by clone 7. I will briefly
consider aspects of two other categories: transcription factors and proteins rich
in basic and/or acidic residues. Sequences of the remaining clones, and
homologies, will be presented in the Appendix.
Table 1. Tat (l-72)-interacting candidate clones isolated via
the two-hybrid system.

CATEGORY A - EGF-LIKE REPEAT-CONTAINING PROTEINS

Clone IP#

Insert size

4

2000 nt
900 nt
1300 nt
1500 nt

7(3 hits)
26
74

Signal strength
(1+to 6+)
6+

Identity of sequence
Fibrillin; EGF-like repeats

6+
4+
5+

EGF-like rpts; novel
Fibulin-2; EGF-like rpts
LTBP-3; EGF-like repeats

CATEGORY B - OTHER CYSTEINE-RICH PROTEINS

Clone ID#

Insert size

49(2 hits)

580 nt

Signal strength
(1+to 6+)
4+

Identity of sequence
novel; Cys-rich

CATEGORY C - TRANSCRIPTON FACTORS

Clone ID#

Insert size

42(2 hits)
54
92
102

1500 nt
1200 nt
850 nt
500 nt

Signal strength
(1+to 6+)
3+
4+
3+
2+

Identity of sequence
HOX l.l
p53
NF-E2
ETO homolog
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Table 1 (continued)
CATEGORY D - BASIC AND/OR ACIDIC PROTEINS

Clone ID#

Insert size

24
27(5 hits)
59(3 hits)

250 nt
800-1400 nt
1200 nt

Signal strength
(1+to 6+)
2+
2+ to 3+
4+

Identity of sequence
(Arg-rich)linker sequence
SF2P32 (splicing factor)
B23 (nucleolar protein)

CATEGORY E - PROLINE-RICH PROTEINS

Clone ID#
25
54
100(2 hits)

Insert size

Signal strength
(1+to 6+)
4+
4+
2+

375 nt
1200 nt
600 nt

Identity of sequence
SAP62 (splicing factor)
p53
low homology to myosin

CATEGORY F - OTHER PROTEINS

Signal strength
(1+to 6+)

Clone ID#

Insert size

44
77

2200 nt
1400 nt

2+
4+

90
97

1200 nt
600 nt

2+
3+

111
122
125

900 nt
900 nt
800 nt

3+
2+
3+

Identity of sequence
homol. to G3PAT
homol. to
collagen alpha-2 (IX)
Ferritin
3'UTR identical to
PDGF-A 3TJTR
Keratin (epidermal type I)
no homology
(B2 repeat)

Note that several of these clones will provide starting points for future
research.
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1. Tat "interacts with" EGF-like repeat-containing proteins.
Our screening revealed strong Tat interaction with four proteins of the
ECM, all of which contain multiple EGF-like repeats. These repeats contain
an array of cysteine residues found in many extracellular proteins and in the
extracellular domain of many transmembrane proteins, often in multiple
copies (Campbell and Bork, 1993). Two of these clones are fibrillin and
fibulin-2, previously-characterized ECM proteins. A third clone, latent TGF-6
binding protein 3 (LTBP-3), was recently isolated (Yin et al., 1995). Clone 7,
isolated three times, represents a novel sequence. Colonies harboring the Tat
and clone 7 fusion plasmids turned blue on colony lift and X-gal incubation
within fifteen minutes, making this interaction one of the strongest detected.
A chicken homolog of clone 7 was reported to the Genbank database in
January 1995, while I was conducting follow-up studies. A rat homolog was
also reported to Genbank in February 1996.
I chose to pursue this class of Tat-interacting protein because of the
possibility that Tat-ECM interactions underlie several of Tat's nontranscriptional effects on mammalian cells. These effects include its role in
the growth of AIDS-related Kaposi's Sarcoma and also its pleiotropic effects
when expressed in heterologous cell types and in transgenic mice. Currently,
there is no explanation for these effects. My results offered an opportunity to
provide such an explanation, since components of the ECM are known to
play regulatory roles in cellular processes, as well as structural roles (reviewed
by Adams and Watt, 1993; Bosenberg and Massague, 1993).
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Our goals regarding this clone were to:
1. Analyze its expression pattern in different mouse tissues.
2. Obtain the entire cDNA sequence.
3. Search for clone 7 interactors via the two-hybrid system.
4. Identify the region of Tat with which it interacts.
5. Demonstrate direct interaction (or lack of it) in vitro between Tat and clone
7 peptides.
A. Expression pattern of clone 7 mRNA in mouse tissues
I probed a mouse Northern blot with a random-primed, radiolabeled
fragment of the original clone 7 cDNA (Figure 10). This experiment revealed
that the clone 7 mRNA is about 3.4 kB in length and is expressed strongly in
brain and weakly in testis. It is possible that the weak signal seen in testis
represents neural tissue.
B. Cloning of the cDNA sequence
Since it bound to a 3.4 kB mRNA, my initial fragment of about 1200
nucleotides left much of this novel cDNA sequence to be cloned. I first
amplified clone 7 PCR products, with partial overlap of my initial sequence,
from the GAL4AD fusion library. Using nested primers corresponding to the
5' end of the first fragment and to the vector, I isolated a product of 650
additional nucleotides. This strategy succeeded only once. A long cDNA,
such as the 3.4 kB cDNA of clone 7, is unlikely to be isolated whole from a
cDNA library. Therefore, I chose to amplify the remaining cDNA from total
mouse RNA.
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I first applied the spurious-PCR method of Struck and Collins (1994).
Briefly, this procedure employs two primers (one nested) corresponding to
the known, 3' end of the cDNA and employs a "spurious," heterologous
primer for weak priming of the unknown, 5' end of the cDNA. Although the
first reaction is very inefficient and yields very few PCR products specific for
the desired cDNA, amplification with the second, nested 3' primer amplifies
these products preferentially, allowing isolation of a piece of the unknown 5'
end of the cDNA.
For the 5' "spurious" primers, I used oligonucleotides corresponding to
various regions of the HIV genome. These primers were originally designed
for other purposes and have convenient restriction sites built into them.
They offer the advantage of not binding tightly to any mouse transcribed
sequences, thereby eliminating a high background of priming.
Approximately half of the PCR products which I isolated and cloned in
this manner were true extensions of the clone 7 cDNA. The other half
represent mispriming events. Usually, the misprimed products exhibited
homology with the nested 3' primers. For example, I isolated a fragment
from the mouse tenascin cDNA, which encodes EGF-like repeats (Erickson
and Bourdon, 1989) and competed for binding of the nested primers.
The fragments obtained by this method range from about 70
nucleotides to about 350 nucleotides. This small size might be due to the
limited length of the random-primed cDNA fragments which serve as the
template for the PCR reaction, although I used a reverse transcription
protocol designed to obtain maximum length products (Ausubel et al., 1994).
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After providing more than 900 nucleotides of cDNA sequence (up to
the presumptive 15th codon of clone 7, by comparison with the chicken
homolog), this spurious-PCR method repeatedly failed to give us a fragment
corresponding to the last fourteen codons and the 5' UTR of the clone 7
transcript. I used the 5' Amplifinder RACE-PCR (Rapid Amplification of
CDNA Ends) protocol (Clontech) to amplify and clone this final piece. This
procedure involves ligation of a DNA primer to the 3' end of first-strand
reverse transcription product to enable subsequent amplification of the
desired sequence as a PCR product.
The protein deduced from the clone 7 ORF sequence (Figure 11) is 820
amino acids long, with an isoelectric point of 5.6 due to its 108 strongly
acidic residues. It also contains 88 cysteine residues, most of which are
present within either the 9 EGF-like repeats or the C-terminal region with
homology to the procollagen-alpha 1 domain of thrombospondin. This
region of the clone 7 protein has greater homology with thrombospondin
than with procollagen. The N-terminal 224 amino acids contain six "LxL"
motifs (two leucine residues separated by a single amino acid). Also, the
protein is relatively rich in glycine residues, of which there are 61.
The EGF-like repeats begin at amino acid 316 and end at amino acid
682; they range in size from 28 to 46 residues. Amino acids 707-758 display
50% sequence identity with the procollagen-alpha 1 repeat of
thrombospondin; the position of the nine cysteine residues and two
asparagine and one valine residue are identical. Several of the EGF-like
repeats (numbers 4, 5, 7, and 8) display homology with the calcium-binding
consensus sequence discussed by Rao et al. (1995).

85

The 3' UTR of the clone 7 message is approximately 170 nucleotides
long (in my clones) and contains an interesting AU-rich repeat - (AAAU)5
AAAAA - at positions 2562-2587 of the mRNA. This sequence is reminiscent
of the AU-rich sequences found in the 3' UTR of many cytokine pre-mRNAs
and which play a role in regulating the expression and degradation of such
mRNAs (Stoecklin et al., 1994; Lagnado et al., 1994). The AU-rich sequence in
the clone 7 3' UTR, however, is found in intronic sequences of several other
mammalian mRNAs, including those encoding human prothrombin,
human cytokeratin, and human eosinophil major basic protein. There is no
immediately apparent significance to this homology, nor is it evident that the
AU-rich sequence in the clone 7 3' UTR plays a role in regulation of the
mRNA expression. However, it is an interesting possibility and could be
investigated in the future.
The 5' UTR of the clone 7 cDNA includes a short open reading frame
consisting of an ATG, another codon, and a stop codon. This ORF ends four
nucleotides upstream of the presumptive ATG which begins the 819-amino
acid ORF of the clone 7 protein. Such short ORFs within the 5' UTR of
mRNAs are not uncommon and occasionally serve to regulate expression of
the mRNA (Geballe and Morris, 1994), usually through translational means.
The sequence immediately surrounding the ATG of the clone 7 ORF is not an
optimal Kozak sequence: (Kozak, 1991).
C. Two-hybrid search for clone 7-interacting proteins
Apart from inferences drawn from its amino acid sequence, I know
nothing of the function of this novel gene product. Two-hybrid interactions
of the clone 7 gene product with cDNA library-encoded proteins might
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inform us of processes in which it is involved. For example, many ECM
proteins effect both structural and regulatory roles by protein-protein
interactions (Sage and Bomstein, 1991).
The original fragment of clone 7 cDNA was about 1200 nucleotides
long, with an open reading frame of about 900 nucleotides. This fragment
was subjected to PCR to attach a PstI site at its 5' end, as it contained an
internal Sail site which precluded in-frame cloning of the original Sall-Notl
fragment. The modified fragment was cloned into the search vector pPC62,
which fuses it to the GAL4DBD. Transformation of this search plasmid into a
two-hybrid reporter strain of yeast resulted in strong reporter gene activation:
two-hybrid reporter colonies bearing only this plasmid are strongly His+ and,
upon colony lift and X-gal incubation, turn blue within fifteen minutes.
I considered that this result might represent contamination with a 6galactosidase-producing yeast strain. The experiment was therefore repeated
twice, using separate stocks of Y153. When both of these experiments gave
results identical to the first, I realized that the clone 7 cDNA fragment
strongly activates reporter gene transcription when localized to the promoter
by the GAL4 DBD. This result raises the possibility that Tat and the clone 7
protein interact indirectly via components of the transcription complex.
However, learning about the function of clone 7 by identifying proteins
which interact with it, remains a valuable goal in itself. The initial clone 7GAL4 DBD fusion plasmid was not useful for two-hybrid searches, since all
colonies containing this plasmid display activation of both reporter genes. I
therefore fused a portion of the first 5' PCR extension into the search vector
as an in-frame fusion with the GAL4DBD. This new plasmid did not activate
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transcription of the reporter genes and was therefore used to conduct twohybrid searches in reporter yeast strains Y153 and HF7c.
Approximately 300,000 transformants were analyzed in the strain Y153.
All colonies grew to about the same (small) size, indicating that no clone 7
interactors were present in the library clones screened. Therefore, I have not
yet learned (from this method) what proteins might bind to the clone 7 gene
product. Further searches with this fragment and other clone 7 fragments
may reveal interactions of this protein with other members of the library,
since this search was not exhaustive. Knowledge of clone 7-interacting
proteins would suggest possible functions for this novel gene product and
experimental approaches for testing functional hypotheses.
D. In vitro binding of Tat and clone 7 peptides
While the two-hybrid system is extremely useful for rapid
identification of library-encoded proteins which interact with a protein of
interest, it is desirable to demonstrate a putative interaction in another, more
direct manner. One method for accomplishing this is to produce both
proteins in bacteria and test the isolated proteins for in vitro binding and gel
mobility shift. A popular tool for production of such proteins is to tag each
with six histidine residues, allowing purification of the desired peptide from
bacterial lysate via the nickel-binding properties of the six-histidine tag (Croi
et al., 1994).
Clone 7 peptide (about 300 amino acids long) was expressed and
isolated in this manner and exposed in vitro to Tat peptides expressed in the
same system. The reactions were then run on a native polyacrylamide gel in
order to determine the binding between the two, if any. No interaction was

89
detected in the form of a mobility shift of either the clone 7 peptide or the Tat
peptides. However, these reactions were performed using peptides isolated
under denaturing conditions; while the reaction buffer used was neutral, the
denaturant remaining from the isolation process may have prevented
protein-protein interaction. Unfortunately, non-denaturing isolation
procedures did not yield satisfactory amounts of the Tat and clone 7 peptides;
the conditions of the non-denaturing isolation are much gentler, physically,
and apparently the yield of histidine-tagged protein suffers accordingly.
Another possibility is that the Tat peptides produced in this manner were not
functional for binding studies; Tat is notoriously difficult to produce, either
chemically or bacterially, in a functional form (Chun et al., 1990; Green and
Lowenstein, 1988).
However, the clone 7 peptides will be useful in future study of this
protein. For example, such peptides will be used to obtain antisera to clone 7,
enabling immunological localization and functional studies. Also, this
peptide might be used to isolate the yeast transcription factor(s) to which it
binds, since one or more of these factors may "bridge" the interaction between
Tat and the clone 7 peptide.
2. Tat "interacts with" transcription factors
As detailed in the Introduction, Tat is believed to bind to one or several
proteins of the multicomponent transcription complex. When I initiated
these studies, Tat's interaction with TBP (Kashanchi et al., 1994) and Spl
(Jeang et al., 1993) were not known. These interactions, however, do not
preclude the possibility that Tat might bind to other proteins involved in
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transcription. In fact, it is common for transcription factors to bind many
different proteins (Frankel and Kim, 1991).
Our screen yielded four different transcription factors of diverse
character. These were p53, a known tumor suppressor; Hox 1.11, a homeobox
protein; a novel homolog of ETO, a transcription factor of erythroid
precursors; and a clone with partial identity with NF-E2, a nuclear factor
involved in transcription of erythrocyte-specific genes. These proteins do not
likely represent the critical factor in Tat's transcriptional activation: all but p53
are expressed only in non-lymphoid tissues, and none of them functions in
general transcription mechanisms. From the first, I suspected that these
interactions might be indirect, given the propensity of many transcription
factors to contact multiple proteins within the transcription complex (Frankel
and Kim, 1991; Zawel and Reinberg, 1995). Because I am skeptical regarding
the relevance of these four clones to Tat's role in HIV transactivation, I have
not pursued any of these clones extensively. Clone 102 is a novel gene and
might represent an interesting cloning project.
Clones 42 and 70 both contain about 80% of the coding sequence of the
homeobox protein Hox 1.11 (Nazarali et al., 1992). The region of Hox 1.11
encoded in the library fusion includes the homeodomain and a hexapeptide
conserved between most homeobox proteins. This clone, isolated twice (the
clones are not identical at their 5' ends) encodes the homeobox protein Hox
1.11 (cloned originally by Nazarali et al., 1992).
Hox 1.11 is involved in differentiation along the anteroposterior axis of
the mammalian embryo and is expressed mainly during development, as are
most homeobox proteins (Nazarali et al., 1992). All known homeodomain
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proteins exert transcriptional control (positive or negative) on a set of genes
to whose enhancers they bind; the DNA-binding property resides in the
namesake homeodomain region of the protein (Levine and Hoey, 1988;
Kessel and Gruss, 1990). Some homeodomain proteins are expressed in
adults as well as in developing embryonic tissues. These may participate in
maintenance of differentiation and perhaps in other processes (McGinnnis
and Krumlauf, 1992).
Clone 54 is a full-length cDNA fusion of the mammalian tumor
suppressor protein p53. It encompasses the start codon and most of the 5'
. UTR of the p53 mRNA. It is unusual to obtain a full-length cDNA from a
libraiy biased toward the 3' end of transcripts, unless the sequence is short or
sequences near the N-terminus are required to encode an interacting protein.
I therefore tested the ability of the amino-terminal seventy amino acids of p53
to interact with Tat by constructing and cloning a PCR fragment fusing these
amino acids to the GAL4AD. No such interaction was apparent in my twohybrid analysis of the new construct, indicating that the interaction with Tat
either is mediated by another region of p53 or that the interaction requires
another region in addition to the N-terminus of p53. Colonies bearing the
p53 amino-terminus-GAL4AD fusion and the Tat-GAL4DBD fusion failed to
give detectable HIS3 or fi-galactosidase signal even after prolonged incubation.
The primary sequence of p53 includes a run of proline residues; this
property is shared by a number of other Tat-interacting clones. This region,
however, was present in the amino-terminal p53 construct, which did not
interact with Tat. The structure of this peptide alone might differ from its
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structure in the full-length p53 protein. Alternatively, another region of p53
might be involved in the interaction with Tat, direct or indirect.
A portion of clone 92 is identical to the tissue-specific component of the
mammalian transcription factor NF-E2. This protein (p45) is expressed in
hematopoietic tissues and is a basic-leucine zipper protein (Andrews et al.,
1993). Because of an internal Sail site within the cDNA, I have sequenced
only a portion of this clone. Another region of my clone does not match the
known sequence of the NF-E2 gene, whose primary transcript is believed to
undergo extensive alternative splicing (Pischedda et al., 1995). However, this
portion of the transcript is 65 nucleotides 3' of the stop codon of the NF-E2
sequence. The clone which I have isolated may represent an alternative
splicing event which alters the sequence of the 3' UTR of the NF-E2 mRNA.
The protein p45 appears to dimerize with a widely-expressed partner
protein to form the active complex NF-E2. It also binds to several other
transcriptional partners (Igarashi et al., 1994). This highlights again the
capacity of many of my Tat-interacting clones to form complexes within the
transcriptional machinery. It also underscores my suspicion that the
association of Tat with these factors is indirect, mediated by a yeast
transcriptional component. A recent study of mice lacking the p45 subunit
indicates that this protein is likely involved in regulation of platelet
development as well as erythrocyte development (Shivdasani et al., 1995).
Clone 102 appears to be a new homolog of the putative transcription
factor CBFA2T1/ETO (Niwa-Kawakita et al., 1995; Erickson et al., 1994). A 500
nucleotide region of this clone displays approximately 60% homogy with this
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gene (Figure 12); this sequence similarity is 67% at the amino acid level
(Figure 13). The DNA sequence 3' of this region bears much lower homology
with the CBFA2T1/ETO gene (less than 30%). This clone might represent an
attractive subject for a short cloning project.
3. Tat interacts with certain acidic and/or basic proteins
The remaining Tat-interacting clones include a number of proteins
with regions of largely acidic or largely basic amino acids (or both). Two of
these proteins - B23 and SF2P32 - have already been shown to bind to the
HIV-1 Rev protein (Fankhauser et al., 1991; Luo et al., 1994) and were isolated
repeatedly in my screening. Fridell and colleagues (1995) also found that Tat
binds to SF2P32 in the two-hybrid system. The basic region of Tat is similar in
character to that of Rev, and both basic regions mediate nuclear and nucleolar
localization; they may then bind to similar proteins. The known direct
interaction of Rev and B23 makes feasible a direct interaction between Tat and
B23.
Three separate clones (59, 72 and 115) encode the major mammalian
nucleolar protein B23. All three extend to the same point near the end of the
5' UTR of B23 cDNA. A short mRNA such as the B23 transcript (which totals
about 1000 nucleotides) might yield largely full-length cDNAs upon oligo-dT
priming, as was used for the generation of this library by Chevray and
Nathans (1992). Therefore, I believe that these clones are not necessarily
//siblings,, but represent independent cloning events, supporting the initial
observation that Tat binds to B23.
The basic domain of Rev is believed to mediate interaction with B23
(Fankhauser et al., 1989); I strongly suspected that the basic domain of Tat
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would bind to B23, by analogy with the Rev-1323 interaction. Therefore, I
constructed a Tat gene encoding amino acids 49-72, which consists primarily
of the basic domain, for fusion to the GAL4DBD. The full-length RevGAL4DBD construct was used for comparison. The full-length Rev fusion
protein interacted with B23, as expected; and this interaction was comparable
in strength to that of the Tat fusion with B23. A control construct (encoding
the carboxy-terminal half of Rev, which lacks the basic domain) did not yield
a signal, confirming the specificity of the interaction and suggesting that it is
indeed the basic region of Rev (and of Tat) which mediates binding to B23.
I sought to demonstrate in vitro the interaction between B23 and Tat.
DNA segments encoding the first Tat exon (amino acids 1-72) and smaller
portions (amino acids 1-48 and 49-72) were constructed via PCR, and then
cloned and sequenced in Bluescript. These fragments were then subcloned
into both the GAL4DBD fusion vector and a bacterial expression vector
(pQE32) which tags the peptide with six histidine residues at the amino
terminus. Purification of the Tat peptides and the B23 peptides from the
bacterial expression system yielded high amounts of the Tat peptides and of
the B23 protein. These peptides were incubated together in solution and then
run on a native polyacrylamide gel.
I have failed to demonstrate interaction between the Tat and B23
peptides; however, the denaturing solvent in which these peptides were
isolated and purified may have interfered with subsequent interactions.
Further work with these peptides may demonstrate interaction between B23
and the basic domain of Tat, as I expect, based on my two-hybrid work.
However, as mentioned earlier, it is possible that my Tat peptides, although
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produced in adequate quantity, were not functional, given the known
difficulties in producing functional Tat peptides (Chun et al., 1990; Green and
Lowenstein, 1988).
Five clones (27, 43, 52, 55, and 119) represent the p32 subunit of the
conserved mammalian splicing factor SF2. No two are identical, although
the 5' ends of all five are close to one another. The smallest clone is 55, which
lacks only ten codons of the entire coding sequence. This may indicate that a
nearly full-length protein is needed for interaction with Tat. As with B23,1
demonstrated that the basic domain of Tat is responsible for binding to
SF2P32.
Luo and Peterlin (1993), as mentioned, reported that Rev and SF2P32
interact in the two-hybrid system. They further demonstrated that antisense
diminution of SF2P32 expression in cultured cells diminished Rev function.
However, it is possible that this diminution represents a non-specific effect on
cellular splicing. The significance of Tat-SF2P32 interaction, as observed by
Fridell et al. (1994) and ourselves, is uncertain. One possibility is that the
interaction reflects the coordination of transcription and splicing (JimenezGarcia and Spector, 1993). Alternatively, the interaction of Tat and SF2P32
may not occur in vivo.
D. Other Tat studies in yeast
One of my initial goals was to characterize the transcriptional activity
of Tat in yeast cells. Neither the TAR-lacZ functional system (see Appendix)
nor my two-hybrid work has achieved this goal. Two other methods of
investigating the function of Tat in yeast are (1) to study the activation of
transcription effected by the Tat 1-48 - GAL4AD fusion construct, and (2) to
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screen for yeast-encoded Tat-interacting factors in the two-hybrid system itself.
I have performed preliminary investigations along both of these paths.
1. Study of Tat (1-48) transcriptional activation in yeast
As mentioned earlier, the Tat 1-72 protein does not activate
transcription when localized to the promoter of a reporter gene in the twohybrid system. However, Subramanian et al. (1994) showed that Tat 1-48 is
capable of activating transcription from a GAL4 promoter when fused to the
GAL4DBD. I confirmed this report experimentally. Interestingly, Tat 1-48 is a
relatively weak activator: colonies bearing the Tat 1-48-GAL4DBD construct
turn blue in an X-gal assay only with overnight incubation. I also observed
that Tat 1-52 does not activate transcription as a GAL4DBD fusion; colonies
bearing this fusion do not display activation of reporter genes even with
prolonged incubation.
2. Tat-interacting proteins from a yeast genomic library
I attempted to identify the yeast transcription factor to which Tat (1-72)
binds by screening a yeast genomic DNA-GAL4AD fusion library. The Tat 172 gene was subcloned into a vector which fuses it to the LexA DNA-binding
domain. This eliminates isolation of the yeast GAL4 gene (and fragments of
it) during screening of the yeast genomic library. Screening of approximately
200,000 colonies revealed four colonies which evidenced activation of the
GAL4 - lacZ reporter gene. Cloning and sequencing of these four revealed
that the three weaker interactors were CDC7, CDC25 and the opposite strand
of a portion of the SIP4 gene.
I was unable, despite numerous attempts, to transform bacteria with
yeast plasmid DNA from the strong interactor colony. I therefore carried out
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PCR, using the long-PCR reagent Taq Extender (Promega) to amplify the
insert of this clone directly from the plasmid lysate. These reactions required
several re-amplifications and yielded several different DNA fragments,
ranging in size from one to four kilobases. The fragment which I succeeded
in cloning is identical to the other clone representing the non-coding strand
of the SIP4 gene. This fragment may be a product of contamination rather
than a genuine amplification event. I have not pursued these clones further
due to lack of time and lack of a clear theme explaining the results.

CHAPTER FOUR
DISCUSSION

A. Selection of candidate Tat-interacting clones for further characterization
Our original goal in using the two-hybrid system was to identify one or
several mammalian proteins involved in the transcriptional activation
effected by Tat; I do not believe that I have identified such a factor. The
number of individual clones I obtained (twenty-two) forced me to reconsider
my experimental objectives. It is unlikely that any of these clones represent
effectors of Tat transcriptional activation. However, some might represent
non-transcriptional interactions of Tat; these interactions remain
uncharacterized at the molecular level. Characterization of such interactions
is a worthy goal.
The scope of my screening results precludes detailed characterization of
all twenty-two Tat-interactors. I chose to focus on clone 7, apparently a new
ECM or transmembrane protein (due to its multiple EGF-like repeats;
Campbell and Bork, 1993). Characterizing this clone might provide
information regarding Tat's extracellular effects - for example, its mimicry of
the ECM in AIDS-KS pathogenesis (Ensoli et al., 1994). Alternatively, this
interaction might play a role in Tat's neuropathological effects (Sabatier et al.,
1991), which might involve an interaction of Tat with ECM components of
neural tissue.
I obtained a much wider variety of Tat-interacting factors than I
initially sought. My experience is mirrored by Fridell and colleagues (1995),
who detected eight categories of factors in two-hybrid Tat searches. This wide
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variety of Tat-interacting factors may reflect the modularity of Tat's structure
(discussed earlier) and its involvement with several cellular processes. It
might also indicate that Tat can bind to a yeast factor(s) capable of bridging
interactions with diverse library members.
For example, I identified several transcription factors in the screen.
However, they are not of the type I believe are involved in Tat
transactivation - general transcription factors such as the components of the
TFIID complex (Kashanchi et al., 1994) - and may not bind directly to Tat.
Instead, these proteins might bind to a component(s) of the general yeast
transcriptional machinery to which Tat also binds, thus reconstituting a GAL4
activator through an indirect interaction.
Several other clones may also interact indirectly with Tat, especially the
clone 7 C-terminal fragment and the three other EGF-like repeat-containing
proteins, fibrillin, fibulin-2, and LTBP-3. This possibility is highlighted by the
fact that the clone 7 fragment strongly activates transcription and therefore
must bind to the transcription apparatus. One may postulate that both Tat
and the clone 7 fragment bind to a yeast factor. Indirect interaction is a
heretofore-unreported source of //false-positive,/ two-hybrid interaction
(Bartel et al., 1993).
B. Indirect interactions in the two-hybrid system
Because the two reporter genes in Y153 have different downstream
promoter DNA sequences, library clones which activate transcription of both
genes (in association with the Tat-GAL4DBD fusion) are unlikely to be false
positives which bind weakly to the promoter (Durfee et al., 1993). (Such
proteins are extremely unlikely to bind to two different DNA sequences).
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However, the use of two reporter genes does not prohibit such indirect
interactions as I postulate.
C. The clone 7 protein - a new brain protein containing nine EGF-like repeats
Three of the EGF-like repeat-containing proteins identified in my Tatbinding screen have been cloned and characterized to some degree. Fibrillin
is an extracellular protein found in the ECM of many tissues of the
mammalian body and is critical for the strength of arterial tissue (Pereira et
al., 1993). Marfan's syndrome (weakness of connective tissue, particularly in
the thoracic aorta) is caused by a mutation in one of several EGF-like repeats
within the structure of fibrillin (Maslen et al., 1991). The role of fibulin-2 is
less well-understood; it is found in the basement membrane of many tissues
and also in plasma (Pan et al., 1993). Likewise, the function of the newlyidentified LTBP-3 remains unknown (Yin et al., 1995).
The sequence of my initial clone 7 fragment indicated that it encodes a
new EGF-like repeat-containing protein of the ECM. Its expression primarily
in brain (and possibly peripheral nervous tissue) invited the conjecture that
its binding to Tat might play a role in the neurodegenerative effects of HIV
(Spencer and Price, 1992), which may be due in part to Tat. Tat’s toxicity to
cells of neural origin (Sabatier et al., 1991) strengthens this possibility.
1. Structure of the deduced clone 7 gene product
The deduced protein encoded by the clone 7 cDNA contains nine EGFlike repeats. This motif was first characterized in EGF itself (Savage et al.,
1972). It is now known to reside in a wide variety of extracellular proteins,
many of which are involved in coagulation and fibrinolysis, cell adhesion, or
neural development (Campbell and Bork, 1993).
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EGF-like repeats are loosely homologous - about 30% homology
between any two repeats is average - and consist of an array of six cysteine
residues, distributed over 40 to 50 amino acids, which form three disulfide
bridges. The distance between any two of the cysteine residues is variable.
Campbell and Bork (1993) recently proposed a consensus sequence: xxxxCx27Cxl-4(G/A)xCxl-13ttaxCxCxxGaxl-6GxxCx. ("C" represents a cysteine residue;
the letter "a" represents aromatic residues and "t" denotes non-hydrophobic
residues; "x" is any amino acid). This consensus does not match well the
EGF-like repeats in the clone 7 protein (nor in its avian counterpart, nel),
illustrating the wide variability of this domain in different proteins. The
EGF-like repeats found in the clone 7 protein (and the rat and chicken
homologs) most closely match those in fibrillin and fibulin.
EGF-like repeats are found exclusively in the extracellular region of
proteins, chiefly transmembrane proteins and proteins of the extracellular
matrix. (A recent exception is the finding of EGF-like repeats in several
intracellular enzymes, summarized by Toh, 1989). EGF-like repeats are often
found in multiple copies in large ECM proteins; fibrillin, for example,
contains 47 (Pereira et al., 1993). At least some EGF-like repeats must bind to
calcium in order to function. The Ca^+ ligands may contribute both to
stabilization of the EGF-like structure and directly mediate protein-protein
contacts; an example is fibrillin (Handford et al., 1995; Rao et al., 1995).
Several pathogenic mutations of the human fibrillin gene disrupt the
calcium-binding capability of an EGF-like repeat (Dietz et al., 1993; Hewett et
al., 1993). In such proteins, EGF-like repeats may mediate interactions which
serve a structural role. Recent work suggests that there may be more than
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one class of calcium-binding EGF-like repeats (Downing et al., 1996). Four of
the EGF-like repeats in the clone 7 protein display sequence characteristics of
the calcium-binding category.
Other EGF-like repeats are believed to mediate protein-protein
interactions which dynamically regulate cellular processes. An example is the
interaction of Notch and Serrate (both EGF-like repeat-containing proteins) in
Drosophila development. This interaction determines the fate of a subsection
of brain tissue at an early point in development (Fehon et al., 1990). Cloning
of the mouse reeler gene (a mutation causing aberrant neuronal patterning
during embryogenesis), whose product contains eight EGF-like repeats
(D'Arcangelo et al., 1995), demonstrates that normal neural activity can be
profoundly dependent on a single EGF-like repeat-containing protein. The
clone 7 protein may also play an role in neural development and function.
Interestingly, there is precedent for the interaction of a microbial gene
product with an EGF-like repeat-containing protein. The diphtheria toxin
molecule binds to the human heparin-binding EGF-like growth factor,
inhibiting the mitogenic activity which is signaled by this protein (Mitamura
et al., 1995). This interaction was mapped to the single EGF-like domain of
the growth factor.
The clone 7 protein contains another region, not an EGF-lke repeat,
which is also rich in cysteine residues. This region shows about 50%
homology to a region of thrombospondin-1. This homology contains a lower
percentage of identical residues if extended N-terminally (about 34%.)
However, additional cysteine residues are in register in this alignment
(Figure 14). This region of clone 7 displays somewhat less homology to a
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portion of von Willebrand factor and even weaker homology with a portion
of several mammalian mucins.
v730
v740
v750
v720
v710
CXHQNGETVYNSGDIW-VQIXRQCRCljQGEVra
C:H ... Y::.:.WV:.C :C:C
. C : :CP : C. : . :P: .EQCPRC
CFH—^NGVQYKNlSEIEWIVEBIIIMiHCOSrSVTICKKVSCPIMPCSNATV^
"340
"350
"360
"370
"330
"320
Figure 14. Alignment of vWF type C repeat of clone 7 deduced amino acid
sequence ((top) with vWF type C repeat of mouse thrombospondin 1
(bottom). Note identity of ten cysteine residues.
Bork (1991) classifies this region as a vWF type C domain. It is found in von
Willebrand factor (which contains two copies), several glycosylated mucins,
thrombospondins, and the propeptides of fibrillar collagens. This domain,
containing nine invariant cysteines within a span of about forty amino acids,
probably mediate homo- and possibly hetero-oligomerization of the proteins
in which it is found (Hunt and Barker, 1987; Voorberg et al., 1991). It might,
then, mediate oligomerization of the clone 7 gene product, either with itself
or with other proteins. It has been implicated in the binding of von
Willebrand Factor to collagen and heparin (Hunt and Barker, 1987).
Thrombospondin, von Willebrand factor, and mucins are extracellular
proteins thought to interact both with other extracellular proteins and with
cell surface proteins (Frazier, 1991; Bomstein, 1992; Ruggeri, 1993).
Thrombospondin is secreted by most epithilial and mesenchymal cells. As its
name implies, thrombospondin is involved in blood clotting but is also
believed to play an important role in regulation of angiogenesis. A peptide
containing the thrombospondin vWF type C domain increased levels of
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plasminogen activator inhibitor in endothelial cells (a marker of
angiogenesis) (Bagavandoss et al., 1993). Another report indicates that a
seven amino acid peptide from this region can block in vitro angiogenesis at
micromolar concentrations (Tolsma et al., 1994).
This region of thrombospondin contains the cysteine-rich vWF type C
repeat homologous to the C-terminus of the clone 7 protein. I suspected,
then, that clone 7 might play a role in the etiology of Kaposi's Sarcoma, a
tumor of aberrant angiogenesis (Gottlieb and Ackerman, 1982). The restricted
expression of clone 7 mRNA in nervous tissue, and perhaps in testis, argues
against such a role, since KS arises in many tissues other than brain.
However, it remains possible that clone 7 exerts an extracellular influence on
cellular activity, as do other proteins containing either EGF-like repeats or
vWF type C domains. Of known extracellular proteins, only
thrombospondin and clone 7 (and the chicken and rat homologs) contain
both types of repeat. This fact suggests a regulatory role for the clone 7 protein
(as for thrombospondin), as opposed to a primarily structural role (as for
fibrillin, which does not contain vWF type C repeats). The N-terminus of the
clone 7 protein (amino acids 112-214) displays about 25% homology to another
region of homology between thrombospondin and procollagen. This region
is not cysteine-rich but contains eleven leucine residues; the positions of four
of these are conserved between clone 7 and thrombospondin.
Bork (1991) notes that extracellular protein domains are often
characterized by unique patterns of cysteine residues; many contain multiple
repeats of several different cysteine-rich domains. The structure of clone 7,
then, is in keeping with that of other extracellular proteins.
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As discussed earlier. Tat contains a cysteine-rich sequence essential for
its transcriptional function (Rice and Carlotti, 1990b). It is interesting that
clone 7, isolated by interaction with Tat, contains two different types of
cysteine-rich motifs and is itself rich in cysteines. It is even more interesting
that the fragment of clone 7 which interacts with Tat is also capable of
strongly activating transcription when tethered to a yeast promoter. While
there is little evidence to support Tat dimerization in mammalian cells, the
cysteine-rich region of Tat may mediate intramolecular disulfide bonds
(Frankel et al., 1991). In yeast cells, this region of Tat might be more available
for binding to other proteins, possibly to other cysteine-rich motifs.
Alternatively, a yeast factor(s) bearing an affinity for such motifs might bind
to both partners of a two-hybrid pair (both rich in cysteine residues) and
thereby "bridge" their interaction.
2. Two-hybrid screening for clone 7-interacting proteins
A surprising result of my experiments was that the clone 7 fragment,
originally isolated via its interaction with Tat, strongly activated transcription
when localized to a reporter gene promoter. How does a presumptive ECM
protein function as a transcriptional activator in yeast? It bears no homology
to any known class of transcriptional activator (Tjian and Maniatis, 1994), Yet
the levels of transcription which it engenders are comparable to those seen
with the native GAL4 protein, as measured by the colony lift assay. These
results strongly suggest that the C-terminal fragment of the clone 7 protein
binds to a yeast transcription factor(s).
An important implication is that the interaction between Tat and the
clone 7 peptide may be indirect; that is, that both of them bind to a common
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factor which acts as a "bridge" between them. Alternatively, the C-terminal
portion of the clone 7 protein may bind to a number of transcription factors,
including both Tat and a general transcription factor found in yeast. My
present data do not allow discrimination between these possibilities.
However, it seems more reasonable to conclude that clone 7 binds to a general
transcription factor which then binds to Tat, given the known interaction of
Tat with TBP, a protein found within the multicomponent general
transcription factor TFIID (Kashanchi et al., 1994).
I recently learned that the chicken nel protein (of which clone 7 is the
mouse homolog) (Matsuhashi et al., 1995) was detected in a two-hybrid screen
of the chicken transcription factor qin (Chang et al., 1995; personal
communication. Dr. Cathy Chang). Further, both the clone 7 gene product
and the chicken nel protein strongly activate transcription of two-hybrid
reporter genes in yeast when tethered to the promoter (our results and results
communicated to us by C. Chang). These results strengthen the hypothesis
that the clone 7 protein (and its homologs) contact a general transcription
factor which can then bind other proteins, producing an indirect interaction.
'.c.

Although this argument is not conclusive, I think it possible that
proteins such as my clone 7 and the nel protein (and probably also fibrillin,
fibulin-2 and LTBP-3, the other EGF-like repeat-containing proteins which I
identified) bind to an endogenous yeast protein to which Tat also binds.
Clones 49/53 and 111, which are cysteine-rich, might also have been detected
in this way. The only common feature of these proteins seems to be their
cysteine-richness. No known class of transcriptional activators clearly fits this
description. Alternatively, Tat may bind directly to all of these proteins due
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to their cysteine-richness, and these proteins may in turn bind to a yeast
transcription factor. (Intra- and inter-protein interaction in proteins of the
extracellular matrix are often mediated by amino acid domains characterized
by a relative abundance of cysteine residues).
I have potentially identified a new class of transcriptional activation
domains: the EGF-like repeats (and possibly certain other cysteine-rich
domains) found in extracellular proteins. This is a remarkable and unusual
source for so strong a transcriptional activation domain. My finding may
reflect the existence of an uncharacterized class of cellular transcription factors
whose function depends on an array of cysteines similar to those found in
EGF-like repeats. Genetic studies in yeast might reveal more details of the
mechanism of this novel type of activation domain.
3. A new class of false positives in two-hybrid screening
I also have postulated a new class of false positives in the yeast twohybrid system: those which occur through a "bridge" factor endogenous to the
yeast cells. Such indirect interactions have not yet been described (Bartel et
al., 1993). Most false positives occur when the library cDNA-GAL4DBD fusion
protein binds weakly to the downstream promoter sequence of the reporter
gene, engendering transactivation of the gene independent of interaction
with the protein under investigation. The use of strains bearing two reporter
genes (with different promoter sequences) eliminates these false positives
upon assay of the second reporter gene (B-galactosidase activity).
However, the use of two reporter genes would not eliminate this
indirect type of interaction. Such indirect interactions are revealed when the
cDNA-encoded factor can itself bind to the transcriptional apparatus - as can
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the C-terminal clone 7 peptide - or when direct physical interaction cannot be
demonstrated (e.g., bacterial peptides do not bind in vitro to one another).
Investigators must bear in mind such indirect interactions when analyzing
results obtained via the two-hybrid system. This system is not a foolproof
method for proving protein-protein interaction. Supporting data might
include functional corroboration of the interaction or direct measurement of
interaction (e.g., in vitro peptide binding studies).
4. Function of the clone 7 gene product
I cannot say with certainty whether Tat binds directly or indirectly to
the clone 7 protein. If the interaction is indirect, then it is unlikely that Tatclone 7 interaction plays any role in HIV biology. If the interaction is direct,
then Tat binding to EGF-like repeats may underlie a number of Tat's
extracellular effects. Regardless, the clone 7 protein is worthy of interest on its
own merits as a novel brain ECM protein of unknown function.
I am still faced with the following questions: What is the clone 7 gene
product? What function(s) does it serve in the developing and the adult
mouse? Several other EGF-like repeat-containing proteins are known to
perform critical roles in neural development, as mentioned.

However, most

of these are not expressed (or are expressed at extremely low levels) in the
adult mouse. Such is clearly not the case for clone 7, which is strongly
expressed in adult brain and probably plays a role in functioning of adult
neural tissue. Clone 7 may play an additional role in developing neural
tissue. Matsuhashi and colleagues (1995) describe the presence of the nel
protein in both central and peripheral nervous tissue of the chicken until
hatching; thereafter, the protein is expressed only in brain and retina.

Ill
Many EGF-like repeats seem to mediate protein-protein interactions
(Campbell and Bork, 1993). I have observed that a novel protein, containing
multiple copies of this extracellular motif, strongly activates transcription in
yeast when localized to promoter DNA. Presumably it must bind to a
component(s) of the yeast transcriptional apparatus, a function far divorced
from the normal role of these repeats (Campbell and Bork, 1993). These
results may imply that some EGF-like repeats are promiscuous in their
protein-binding capacity.
Perhaps the most direct way of assessing function of the clone 7 gene
product is analysis of mice lacking a functional copy of its gene - the
knockout mouse (Bronson and Smithies, 1994). Mice homozygous for a
disrupted Notchl gene die before day 12 of development and display
widespread death of brain neurons, despite normal overall brain patterning
(Swiatek et al., 1994). The known phenotype of the reeler mouse, which
preceded cloning of the gene, offers another example (Rugarli and Ballabio,
1995). I plan to obtain a clone 7 knockout mouse, in collaboration with Dr.
Jeff Mann at the City of Hope.
It might be possible to identify both the amino acids of clone 7 which
are crucial to this activation, and the yeast protein(s) to which it binds, by
further experimentation with the C-terminal portion of the clone 7 protein.
For example, the clone 7 fragment could be randomly mutagenized (or
targeted deletions might be made) in a search for the minimal domain and
crucial residues involved in transactivation.

Such knowledge might enable

identification of cysteine-rich cellular components which normally function
in transcription and whose activity is mimicked by the clone 7 gene product.
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As mentioned earlier, there is no known class of eukaryotic transcriptional
activators whose sequence characteristics fit those of the clone 7 protein.
Another method would be the isolation of yeast proteins binding
directly to the clone 7 peptide. I have used the bacterial His-tagged clone 7
peptide in an attempt to bind such a factor in yeast cell lysate and learn about
the size and number of such factors. I found no strong and specific binding
events.
D. Transcription factors interacting with Tat in the two-hybrid system
As stated earlier, I do not believe that any of the four transcription
factors identified in my Tat-interactor search represents the critical
mammalian transcriptional component which mediates Tat's transactivation
of the HIV LTR. Tat is known to bind the general transcription factor TBP
(Kashanchi et al.,1994), the sequence of which is 80% conserved between yeast
and human (Rowlands et al., 1994). Yeast TBP can assemble with human
TBP-associated proteins into a multiprotein TFIID complex which can effect
activated transcription in vitro (Zhow and Berk, 1995), indicating functional
conservation of this protein between widely separated species. The Tat-GAL4
DNA binding domain fusion protein might, then, bind to the endogenous
yeast TBP. This protein could then act as a "bridge" to trap any libraryencoded transcription factor capable of binding to it. p53, for example, also
binds to the human TBP (Seto et al., 1992).
Therefore, I did not pursue the interactions of Tat with these factors.
However, the Tat-p53 interaction presents interesting possibilities. Wild-type
p53 inhibits transcription from the HIV-1 LTR (Duan et al., 1994; Li et al.,
1994a and 1994b). The primary LTR regions involved in the p53 inhibition
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were the Spl binding site and the TATA box - both of which are central to
Tat-mediated transactivation of the LTR (Berkhout and Jeang, 1992). Tat
likewise inhibits transcription of the p53 promoter (Li et al., 1995). The
known binding of both proteins to TBP may be the link between their
reciprocal inhibitory activities. My discovery of the interaction between p53
and Tat, whether direct or indirect, might indicate a role for p53 in the
regulation of HIV-1 replication and latency.
The possibility exists, then, that Tat and p53 interact in human cells,
either in HIV-infected cells or when Tat is present after being shed by
neighboring infected cells. Apart from this possibility, I do not believe that
the Tat-interacting clones in this category are pertinent to Tat's role in HIV
gene regulation.
E. Interaction of Tat with B23 and SF2P32
Because the basic domain of Tat is similar to that of Rev and because
they both mediate nucleolar localization (Rosen, 1991), it seems certain that
the basic domain of Tat binds to B23, as does the basic domain of Rev
(Fankhauser et al., 1989). To date, evidence for Tat-B23 interaction has been
indirect and speculative (Marasco et al., 1994; Miyazaki et al., 1992). My results
represent more direct proof of a Tat-B23 interaction and allow more confident
analysis of the functional aspects of Tat-B23 interaction.
B23 is proposed to function in assembly of positively-charged preribosomal particles. It may also mediate nuclear accumulation of ribosomal
proteins and/or export of assembled subunits from the nucleus (Melese and
Xue, 1995). The nucleolar dysfunction engendered by Rev (and possibly by
Tat) might involve disruption of B23's role in ribosome biogenesis (Furata et
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al., 1995). Also, B23 is phosphorylated at multiple sites in vivo; it is not clear
whether phosphorylation regulates B23 activity (Shaw and Jordan, 1995). If it
does. Rev and Tat binding might disrupt this regulation.
Another implication of B23 binding to Tat and Rev is that this
interaction itself may localize Tat and Rev to the nucleus. Nuclear
accumulation of proteins in mammalian (and probably eukaryotic) cells is
due to active nuclear retention of proteins, mediated by binding to nuclear
constituents (Schmidt-Zachman et al., 1993; reviewed by Laskey and Dingwall,
1993). Although it appears that nucleolar localization of Tat and Rev is
dispensible for their function (Selby and Peterlin, 1990), nuclear localization is
essential (Hauber et al., 1987). The in vivo nuclear localization of Tat and
Rev may depend on their interaction with B23. If so, disrupting this
interaction might also disrupt Tat and Rev function.
To this end, it would be useful to identify the specific region of B23 to
which Tat binds. A peptide corresponding to this region of B23 might inhibit
Tat function (and possibly also Rev function). It has been postulated that
shuttling nucleolar proteins may act to escort other proteins into the nucleus
(Meier and Blobel, 1990).
Fankhauser et al. (1991) demonstrated that RRE RNA was capable of
dissociating Rev and B23, implying that Rev simply binds to the RRE with
higher affinity than to B23. By analogy. Tat may be unable to bind to both B23
and TAR simultaneously. However, the Tat-TAR interaction differs in
several ways from Rev-RRE binding. First, Tat does not seem to multimerize
on TAR as Rev does on the RRE. Also, Tat-TAR binding in vivo may
involve a cellular factor, whereas Rev-RRE interaction is independent of
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such a requirement. Therefore, it is possible that B23 might not be stripped
from Tat in the presence of TAR RNA. This interaction might, in fact, serve
to inhibit Tat-TAR interaction, particularly if the peptide within B23 which
mediates Tat binding were used independently of the rest of the protein.
SF2P32 contains many basic residues (lysine and arginine) and was
recently demonstrated to bind to the basic domain of Rev via the two-hybrid
system (Luo et al., 1994). Antisense oligonucleotide inhibition of SF2P32
production within HIV-infected cells reduced the efficacy of Rev function.
However, this effect may not be specific to Rev, since p32 is involved in
general splicing mechanisms.
Our finding that the basic domain of Tat also binds to SF2P32 indicates
a lack of stringent sequence requirements for binding of SF2P32 to basic
domains of other proteins. Fridell et al. (1995) also found that Tat binds to
SF2P32 in the two-hybrid system. It is difficult to relate this interaction to
Tat's known transcriptional function. Binding of Tat and SF2P32 may simply
reflect the similarity of the basic domains of Tat and Rev. Alternatively, TatSF2P32 binding in vivo might modulate the interaction of Rev and B23.
F. Other Tat studies in yeast
Tat 1-72 (a potent activator in mammalian cells) does not activate
transcription in yeast cells. If Tat 1-72 binds to transcriptional components, as
I believe it does, then the multiprotein complex that is assembled at the
promoter by Tat 1-72 - GAL4DBD is inactive, either through a positive block
or through lack of a necessary factor(s). Tat 1-48 can bind to some
transcription factor (or factors) in yeast in a way which engenders productive
transcription; Tat 1-72 either fails to bind this factor(s) or binds also another
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factor(s) which renders the transcription complex nonfunctional. The latter
possibility is likely, given my (indirect) evidence that Tat 1-72 does bind to
some yeast transcription factor to which clone 7 also binds.
Tat 1-48 contains the array of cysteines essential to Tat transactivation
(Ruben et al., 1989; Kuppuswamy et al, 1989). The same yeast transcription
factor which, I postulate, binds to the cysteine-rich two-hybrid library clones,
may also bind to the cysteine-rich region of Tat 1-48. This possibility suggests
at least two approaches toward the identification of the hypothetical Tatbinding yeast factor. The first is to identify the yeast factor specifically binding
to Tat 1-48 in the two-hybrid system. Because Tat 1-48 - GAL4DBD activates
transcription only weakly in yeast cells, this objective could be accomplished
by screening for yeast-encoded factors binding to Tat 1-48 in the two-hybrid
system. The second method is to identify yeast-encoded factor(s) binding to
Tat 49-72 which inhibits the transcriptional activation effected by amino acids
1-48. Again, this objective could be accomplished via the two-hybrid system.
G. Yeast factors interacting with Tat in the two-hybrid system
Our screening of the yeast genomic library for Tat 1-72-interacting
factors yielded four candidates. CDC7 is a serine/threonine protein kinase
required for mitotic DNA synthesis (Sclafani et al., 1988); its mechanism of
action is unknown. CDC25 promotes the exchange of GDP for GTP on factors
involved in the initiation of cell division (Jones et al., 1991). ("CDC" denotes
Cell Division Control). Another Tat-interacting factor appears to be encoded
by the opposite strand of the yeast SIP4 gene, which encodes a protein which
interacts with the SNF1 protein kinase (Lesage et al., unpublished). The
identification of CDC7 and CDC25 as potential Tat-binding factors is

117
interesting but offers no clear ground for further experimentation. Also, I do
not know whether the interaction is direct or indirect. Therefore, I have not
pursued these interactions further.

APPENDIX

A. Other Tat-interacting two-hybrid clones
1. Clone 24
Clone 24 represents a fusion of the GAL4 activation domain to the
cDNA of alpha-globin, but the cDNA is inserted in the opposite direction.
The actual in-frame peptide is rich in basic residues (primarily lysine) as well
as leucine residues and extends less than 80 amino acids past the linker. The
interaction with Tat was weak.
2. Clone 25
Clone 25, a strong interactor, is the C-terminal domain of the mouse
homolog of SAP62, a human spliceosome-associated protein (Bennet and
Reed, 1993) The SAP62 protein was originally isolated as a component of
purified spliceosomal complexes and was later cloned (Bennet and Reed,
1993). Its role in splicing (if any) is not yet known.
The C-terminal fragment of SAP62 is not represented in the otherwise
closely homologous yeast protein PRP11 (Chien et al., 1991); it contains 22
proline-rich heptapeptide repeats. The C-terminus might serve a function
other than splicing, such as transcription or translation. However, many of
my clones are rich in proline residues. Tat may interact promiscuously with
such proteins: one class of known transcriptional activators is characterized
by proline-richness (Gerber et al., 1994).
It was intriguing that Tat, a transcriptional activator, bound so strongly
to a protein known to be associated with splicing components. I sought to
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learn more about SAP62 by searching the mouse embryo cDNA library for
proteins interacting with it. I cloned the incomplete SAP62 cDNA into the
search vector PC62 (fusing the partial SAP62 cDNA to the GAL4 DNA-binding
domain) and screened the mouse embryo cDNA library for interacting factors.
None were found in over 500,000 colonies screened. This C-terminal portion
of SAP62 may simply not bind to another protein or may require another
portion of the protein to bind a ligand. It is likely that this protein, isolated as
part of the mammalian splicing complex (Bennet and Reed, 1993), does
interact with other proteins.
3. Clone 44
Clone 44 interacted weakly with Tat; its cDNA sequence is large and has
extensive homology with the enzyme glycerol-3-phosphate acyltransferase
(Shin et al., 1991). The clone contains an internal Sail site, so I do not have
the sequence of this clone at the fusion joint. Because the interaction was
weak and no functional significance was apparent, I did no further work with
this clone.
4. Clone 49/53
Clone 49 (also 53) represents a strong Tat interactor. Its deduced amino
acid sequence is rich in proline residues. The DNA sequence shows about
80% homology to an uncharacterized human fetal lung 5' cDNA fragment
which was obtained as an expressed sequence tag (Sudo et al., 1994).
5. Clone 77
Clone 77 is a strong Tat-interactor whose DNA sequence is novel and
is rich in proline residues. A recent search of the Genbank database revealed
that this cDNA has also been isolated as a maternal transcript encoding a
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possible negative regulator of basic helix-loop-helix proteins (Hwang et al,
1996, unpublished) (submitted to Genbank in March 1996). At present, no
information is published regarding the function of this protein or its
expression pattern; and the relevance of its interaction with Tat is uncertain.
6. Clone 90
Clone 90, a weak interactor, is the heavy chain of ferritin, an iron
binding protein (Yachou et al., 1989). The fusion clone encodes all but thirty
codons of the 181-amino acid ORF. The relevance of this interaction is
unclear.
7. Clone 97
The 3' end of this clone (overlapping the ORF of the library-encoded fusion
protien) contains a 51-nucleotide segment which exhibits 95% homology with
a portion of the S'UTR of rat PDGF-A (Hoppe et al., 1987) (Figure 15).
The ORF of clone 97 displayed no homology with known DNA or protein
sequences; it is possible that the ORF in my clone is in fact 3' of a termination
codon which is not present in my clone. The 3' UTR is increasingly
recognized as a site of important regulatory mechanisms (Wickens, 1993).
Clone 97 might represent a new growth factor or an alternatively-spliced
transcript of the PDGF family. Alternatively, it might be a protein either
required for PDGF-A action or involved in modulation of PDGF-A function;
either of the latter possibilities would make regulation of this gene product in
tandem with that of PDGF-A a reasonable phenomenon. The significance (if
any) of Tat interaction with this novel protein is unknown.
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8. Clone 100/105
Clone 100 was obtained twice and interacts weakly with Tat. The
cDNA contained on these plasmids encodes a protein relatively rich in
proline residues with low homology to non-muscle myosin. It is also about
80% homologous to an uncharacterized human cDNA sequence, isolated as
an expressed sequence tag in brain (Berry et al., 1995).
9. Clone 111
Clone 111 interacted with Tat with medium strength and encodes a
portion of murine epidermal type I keratin (Knapp et al., 1987). The
significance of this interaction is unknown.
_ 10. Clone 122
The deduced amino acid sequence of this clone is rich in proline
residues. A recent search of the Genbank database revealed that this clone
corresponds to the opposite strand of a newly-characterized mouse (and
human) cDNA encoding zyxin, a focal contact protein (Macalma et al., 1996).
As with clone 24 (opposite strand of alpha-globin), insertion of this cDNA in
the opposite direction illustrates that library construction (or any other
procedure) which utilizes PCR (Chevray and Nathans, 1992) can produce
cloning artifacts.
11. Clone 125
Sequencing of clone 125 revealed that the GAL4AD fusion of this
plasmid runs through a B2 element, a repetitive element found in
mammalian genomes which is not thought to serve in a protein-coding
capacity (Ryskov et al., 1993).
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b. Rev-RRE functional system
Prior to my adaptation of the two-hybrid system for study of Tat and
Rev interactions with cellular factors, I constructed a system for expressing
Rev in yeast cells. I also sought to analyze the ability of Rev to inhibit splicing
and enhance transport and translation of an RRE-containing reporter mRNA
in yeast cells. Had this system functioned, it would have served as a method
for genetically identifying genes which alter the Rev-RRE axis of regulation or
which are essential to it (i.e., clones from a mammalian cDNA library would
be transformed into yeast containing this reporter system and individual
colonies assayed for alteration of function by altered fi-galactosidase levels).
I designed a single-plasmid system for expressing an inducible Rev
gene and a constitutive RRE-containing splicing-sensitive reporter gene. (Use
of a single plasmid eliminates variation in copy number of effector and
reporter plasmids). The pLINT plasmid (Legrain and Rosbash, 1989) contains
a small, poorly-spliced intron interrupting two exons of a lacZ reporter
transcript. I inserted the HIV-1 RRE into an Ndel site at the 5' end of exon 2
of the reporter gene.
In my construct, unspliced transcripts are translationally in-frame from
the initiator AUG through the RRE and lacZ portions (see Figure 16). In
contrast, splicing generates a transcript which is out-of-frame. If Rev
functions in yeast cells as it does in mammalian cells, it should enhance figalactosidase expression via blockage of splicing and facilitation of nuclear
export.
The pLint plasmid (Figure 17) contains a unique Xhol site between the
UAS and the downstream promoter elements of the pLint lacZ gene. This
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exon 1

exon 2
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B-galactosidase mRNA

intron

Rev Response Element
Figure 16. RRE-containing reporter gene construct. RRE is inserted into an
Ndel site in the short, artificial intron; S-galactosidase mRNA is only in
frame when intron is retained (splicing inhibited and mRNA transported to
cytplasm and translated.
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Figure 17. The pLint plasmid (Legrain and Rosbash, 1989).
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enabled placement of the Rev gene, bearing its own synthetic downstream
promoter, directly downstream of the GAL UAS. I then cloned into the 3' end
of this fragment the constitutive yeast actin UAS (Munholland et al., 1990) to
effect transcription of the lacZ gene. The 3' end of the Rev gene was also
supplied with consensus transcription termination and polyadenylation
signals (see Methods and Materials).
I determined the effect of Rev on the splicing and subsequent
expression of the reporter mRNA, either with or without the RRE in place
within the reporter construct. Analysis of the fi-galactosidase activity of this
construct showed that the GAL UAS upstream of the Rev gene also drove
galactose-inducible expression of the lacZ reporter gene which lacked the
RRE. No difference in fi-galactosidase activity was observed with and without
RRE; this demonstrates that there was a non-Rev-dependent source of lacZ
expression. I did not pursue this project further, since I had by that time
begun using the two-hybrid system to identify both Tat- and Rev-interacting
factors from the mouse embryo cDNA library.
A valuable lesson from my experience is the interfering effect of the
GAL UAS on the reporter gene downstream of the Rev gene (which was
directly 3' of the GAL UAS). I had thought that the constitutive yeast actin
UAS (which is positioned between the GAL UAS and the li-galactosidase
gene) would prohibit the GAL UAS from effecting transcription of the
reporter gene. However, the GAL UAS proved capable of mediating
transcription of both genes simultaneously. Future studies requiring
expression of two genes in yeast should not attempt expression of both
constructs from the same plasmid.
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C. Tat-TAR and TAR-lacZ functional systems
I constructed a potential Tat-TAR functional system in yeast,
diagrammed in Figure 18. I placed the TAR element within the 5' UTR of a
lacZ reporter gene (in plasmid pRP557, kindly provided by Dr. Roy Parker).
My first goal was to determine whether simultaneous expression of Tat and
this reporter gene would affect expression of the TAR-containing reporter
gene, either transcriptionally or translationally. Such a system would enable
genetic identification of yeast and mammalian genes whose products
modulate Tat function. The second goal was to determine whether the TARlacZ reporter gene might enable screening for members of a mammalian
cDNA library (designed for expression in yeast) which either positively or
negatively modulated the expression of the TAR-containing gene alone,
possibly by binding directly to the TAR element.
The TAR element, placed upstream of the start codon of the lacZ
construct, completely blocked translation of the lacZ ORF. Colonies of yeast
(both JM43 and W303) bearing the control plasmid pRP557 gave high levels of
C-galactosidase activity by the colony lift assay. Colonies bearing the construct
pRP558, which contains a short stem-loop in its S'UTR, gave much lower but
readily detectable levels. Colonies bearing the pRP-TAR plasmid, however,
yielded no fi-galactosidase activity by any assay. This indicates that the TAR
element disrupted either transcription or translation of the reporter gene.
The gene was transcribed (as measured by RT-PCR of the transcript) but no 13galactosidase activity was detectable in these cells. Expression of Tat 1-72 did
not affect expression of the reporter gene at all, as measured by fi-galactosidase
levels.
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TAR's translational inhibition, given its location in the 5' UTR, makes
sense. Several investigators have demonstrated that secondary structure in
the S' UTR of eukaryotic mRNAs severely reduces translational efficiency,
depending on the size of the stem (e.g., Kozak, 1989; reviewed by Donahue
and Cigan, 1990). Bairn and Sherman (1988) suggest that yeast transcripts are
especially sensitive to such inhibition.
However, I had hoped that a low level of expression would be
detected, allowing us to identify TAR-specific (and perhaps non-TAR-specific)
RNA-binding proteins which would inhibit the low level of translation by
virtue of their blockage of the ribosome. Also, Tat expression might have
increased translation through the TAR structure, a hypothesized function of
Tat in mammalian cells.
I was left with a screening system for proteins relieving the total
inhibition of translation by the TAR element in the 5' UTR. I performed one
large-scale screening of this construct with a rat brain cDNA yeast expression
library. However, growth of colonies on galactose (required for expression of
the TAR-lacZ reporter gene) was extremely slow; the colonies were barely
visible after three days of incubation at 30° C. The system is unworkable
without non-galactose-dependent expression of the TAR-reporter mRNA.
Unfortunately, no systems were available with a cloning site in a short, wellcharacterized 5' UTR of a constitutive reporter gene.
I have not further pursued either the Tat-TAR or the TAR-lacZ
systems. I considered placement of the TAR into a reporter gene construct
allowing selection either for or against expression; this is the URA3 gene, on
plasmid pNKY1069, kindly provided by Dr. Nancy Kleckner. If this project
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should be continued later, the advantages of such a selectable reporter gene
should be strongly considered, as should the use of a promoter allowing
growth on glucose.
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